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 Chordoma, an aggressive tumor derived from notochordal remnants, is difficult 
to treat due to its proximity to the spinal cord and brain stem and its resistance to 
conventional treatments, such as radiation and chemotherapy. The development of 
effective treatments requires research at the molecular level, which presumably due to 
its rare diagnosis, is lacking for chordoma. Recent studies have identified potential 
targets for systemic therapy; however, there are currently no drugs approved by the 
Food and Drug Administration (FDA) to treat chordoma. One promising approach is 
to target the cytoskeleton, in order to stall progression and sensitize cells to 
chemotherapeutics. Similar to other cancers, chordoma cells co-express vimentin and 
cytokeratin intermediate filaments (IFs), which have both been found to play roles in 
cell mechanical properties and behaviors and their expression has been associated with 
cancer metastasis, chemoresistance, and poor prognosis. Therefore, we investigated the 
  
functional roles of vimentin and cytokeratin IFs in chordoma cells using RNA 
interference (RNAi).   
 First, we examined whether cytoskeletal disruption by siRNA-mediated 
silencing of vimentin or cytokeratin-8 altered the chordoma phenotype. We determined 
that the vacuolated cytoplasm, a distinguishing feature of chordoma, was dependent on 
cytokeratin-8 IFs. Next, we examined the effects of vimentin and cytokeratin-8 
knockdown on chordoma cell mechanics. We found that chordoma cell stiffness, 
traction forces, and mechanosensitivity to substrate stiffness were all dependent on 
vimentin IFs. These results suggest that vimentin, rather than cytokeratin, IFs play a 
predominant role in chordoma cell mechanobiology. Finally, we analyzed the roles of 
vimentin and cytokeratin-8 IFs in cellular behaviors associated with cancer 
progression. We demonstrated that chordoma cell invasion and expression of the 
biomarker sonic hedgehog were dependent on vimentin. Further, we found that 
decreasing vimentin expression in chordoma cells may increase their sensitivity to 
chemotherapeutics. Because mechanical cues are important determinants of cell 
function, we hypothesize this correlation is in part due to the newly discovered role of 
vimentin IFs in chordoma cell mechanobiology. These results elucidate novel roles of 
vimentin and cytokeratin-8 IFs in chordoma cells, which may assist in the development 
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Chapter 1: Introduction 
 
Chordomas are rare, but aggressive, malignant bone tumors that arise from 
remnants of the embryonic notochord and occur along the length of the spine. Because 
chordomas are resistant to traditional radiation and chemotherapies, the prognosis of 
chordoma generally depends on the success of surgical resection. However, complete 
surgical resection is difficult to accomplish due to the proximity of chordomas to vital 
structures, such as the brain stem and spinal cord. As a result, chordomas are associated 
with high recurrence rates and the median survival time with chordoma is only 
approximately 6 years [1]. In order to develop effective treatments for patients living 
with chordoma, we need to improve our understanding of chordoma at the molecular 
level.  
Many cellular behaviors associated with cancer progression, such as cell 
invasion, are dependent on the cytoskeleton. Therefore, the cytoskeleton may serve as 
a potential target to mitigate malignancy and metastasis. Cancer cells tend to co-express 
vimentin and cytokeratin IFs, indicating a hybrid phenotype that has partially gone 
through the epithelial-to-mesenchymal transition (EMT) or vice versa [2]. Individually, 
vimentin and cytokeratin IFs have been found to play roles in cell mechanical 
properties and processes. For instance, studies of other cell types have shown that both 
vimentin and cytokeratin IFs contribute to cell stiffness [3], [4], and play roles in cell 
traction forces [5], [6], response to mechanical stimuli [7], [8], and migration [9]–[12]. 





extracellular matrix (ECM). Consequently, the increased ECM stiffness characteristic 
of tumors is connected to a malignant cell phenotype [13], [14]. In addition to their 
involvement in cell mechanics, both vimentin and cytokeratin expression have been 
associated with cancer metastasis [15]–[19] and chemoresistance [11], [20]–[22], and 
their co-expression may indicate a more aggressive malignancy [23]. However, the 
functional roles of vimentin and cytokeratin IFs in chordoma cells have not yet been 
reported. The overall goal of this dissertation was to examine the roles of vimentin 
and cytokeratin-8 IFs in the mechanobiology and malignant behaviors of 
chordoma cells using RNA interference (RNAi).  
To accomplish this, our first objective was to investigate whether knockdown 
of vimentin and cytokeratin-8 IFs altered the chordoma cell phenotype. We found that 
optimal knockdown, as measured by qRT-PCR, western blotting, and 
immunofluorescence, was achieved in human chordoma cells derived from the MUG-
Chor1 cell line six days after transfection with siRNA. We discovered that the presence 
of characteristic cytosolic vacuoles, often used to differentiate chordoma from other 
cancers, was dependent on cytokeratin-8 IFs (Chapter 3). Insight into factors that 
function to maintain the chordoma cell phenotype is critical for assisting in the 
development of targeted therapies for chordoma.  
Our second objective was to examine how vimentin and cytokeratin-8 
knockdown, and resulting changes to the vacuolated cytoplasm, affect the biophysical 
interplay between chordoma cells and their surroundings. Specifically, we measured 
their roles in chordoma cell mechanics, traction forces, and mechanosensitivity to 





contribute to chordoma cell stiffness and are involved in generating cell traction forces 
and mechanosensing substrate stiffness (Chapter 4). Because abnormal changes in cell 
and tissue mechanics can lead to disease, determining the involvement of vimentin and 
cytokeratin IFs in chordoma cell mechanobiology may provide insight into chordoma 
progression. 
We ultimately wanted to determine how these mechanical changes affect 
cellular processes and qualities associated with cancer progression. Therefore, our third 
and final objective was to examine the effects of vimentin and cytokeratin-8 
knockdown on chordoma cell migration, invasion, gene expression, and resistance to 
chemotherapy drugs. We found that chordoma cell invasion and the expression of the 
cancer biomarker sonic hedgehog (SHH) were both dependent on vimentin expression 
(Chapter 5). Additionally, our results suggest that decreasing vimentin expression may 
increase the sensitivity of chordoma cells to the chemotherapy drugs cisplatin and 
paclitaxel (Chapter 5). Elucidating biological factors that encourage chordoma 
progression and chemoresistance is essential for the development of effective 
treatments. 
These results identify, for the first time, functional roles of vimentin and 
cytokeratin-8 IFs in chordoma cells and indicate a potential association between 
vimentin expression and chordoma progression. Based on these results, vimentin may 
serve as a potential therapeutic target that could be used in combination with 
conventional chemotherapy to increase cell sensitivity and mitigate metastasis in 
residual cells. Future studies should further investigate the dependence of aggressive 





Chapter 2: Background 
 
2.1 Embryonic Notochord 
 The notochord, a midline structure which serves essential structural and 
signaling roles for embryonic development, is composed of large, vacuolated 
notochordal cells (NCs) that are surrounded by a basement membrane sheath [24]–[26] 
(Figure 2.1a, b, c). Radial constriction provided by the outer membrane sheath on 
osmotically swelling vacuoles of the inner cells is essential for embryonic axis 
elongation and spine morphogenesis [24], [26], [27]. Notochord development is also 
dependent on various molecules. The transcription factors brachyury (T), Sox-5, and 
Sox-6 are required for NC cell survival and differentiation [28], [29]. Additionally, the 
secreted factors SHH and noggin play critical roles in patterning of the axial 
cytoskeleton and neural tube [30], [31]. With embryonic development of the vertebral 
column, notochordal remnants become segmented between vertebral bodies and form 
the immature nucleus pulposus (NP) (Figure 2.1d) [32], [33]. Located at the center of 
the intervertebral disc (IVD), the immature NP is a proteoglycan-rich tissue that 







Figure 2.1: Anatomy and development of the embryonic notochord. (a) Schematic of the 
embryonic notochord illustrating the organization of large, vacuolated cells; (b) Confocal 
image of a cross section of a zebrafish embryo labeled with membrane GFP in the outer and 
inner cells of the notochord. Cross sections were stained with Phalloidin (red) and DAPI (blue). 
V, vacuole; arrowheads show inner cell nuclei. Scale bar: 20 µm; (c) Live confocal image of a 
transgenic membrane GFP (green) zebrafish embryo stained with MED (red) to visualize 
internal membranes. Scale bar: 50 µm; (d) Mid-sagittal sections made in the lumbar vertebral 
column of mouse embryos (E12.5-E15.5). Sections were stained with Alcian Blue and nuclear 





inner annulus (IA), outer annuls (OA), nucleus pulposus (NP), and vertebral bodies (VB). (a, 
b, and c: Adapted from Ellis, K, 2013 [24]; d: Adapted from Smits, P, 2003 [29]).  
 
2.2 Immature and Mature Nucleus Pulposus Cell Phenotypes 
 In some vertebrates such as pigs, rabbits, rats, mice, and non-
chondrodystrophoid dogs, cells of presumed notochordal origin remain in the NP 
throughout life [33], [34]. However, as humans age, the majority of NCs give way to 
smaller, more chondrocyte-like, mature NP cells [35]–[37]. NCs are commonly 
distinguished from mature NP cells by their cytosolic vacuoles (Figure 2.2a, b), larger 
size (25-85m compared to 17-23m), and organization in isolated cell clusters (Figure 
2.2c) [38]–[41]. In addition to their distinct morphology, NCs express phenotypic 
markers such as T brachyury, SHH, N-cadherin, and cytokeratin-8, -18, and -19 [42], 
[40], [43]–[47]. NCs are one of the unique cell types that co-express cytokeratin and 
vimentin IFs (Figure 2.2c) [44], [48]. In contrast, mature NP cells tend to express only 
vimentin IFs [44]. Because cells of the NP are responsible for the synthesis of a 
functional ECM, the cellular transition observed with aging is believed to be involved 






Figure 2.2: Age-associated changes of the NP. (a) Middle transverse sections of rat lumber 
IVDs at 6 (A1) and 20 (B1) weeks old. In the young IVD (A1), there is a distinct separation 
between the NP and the annulus fibrosis (AF) (red arrow). Hematoxylin-Eosin staining shows 
that the young NP contains predominantly vacuolated NCs (A2, red arrows) in an ECM rich in 
hyaluronic acids and proteoglycans (A2, red triangle); whereas the adult NP has a more 
cartilaginous matrix (B2, black triangle) and is sparsely populated with smaller, chondrocyte-
like NP cells (B2, black arrows). (Adapted from Wang, F, 2016 [51]); (b) NP cells from grade 
I and III IVDs. Discs were graded based on the Thompson scale, where grade I NP were 
gelatinous with a clear annular-nuclear demarcation and grade III NP were more fibrous with 
unclear annular-nuclear demarcation. NP tissue was harvested from skeletally mature non-





Cells in grade I NP have large vacuoles, which were surrounded by F-actin. In contrast, cells 
in mature, grade III NP were small, dispersed, and non-vacuolated. (Adapted from Hunter, CJ, 
2003 [40]); (c) Bovine (18– to 24-month-old) NP cells stained for cytokeratin-8 (green), 
vimentin (red), and nuclei (blue). Characteristic of NCs, some NP cells organized in clusters, 
as indicated by an arrowhead, and were also cytokeratin-8 positive. Scale bar: 60 µm. (Adapted 
from Gilson, A, 2010 [41]). 
 
2.3 Chordoma 
 Chordomas are malignant bone tumors that occur along the spine and are most 
commonly found in the sacrococcygeal (pelvic) region and at the base of the skull [52], 
[53]. While rare, chordomas are often recurring and difficult to treat due to their growth 
near vital structures such as the spinal cord and brainstem [1], [54]. Chordomas are 
presumed to originate from remnants of the embryonic notochord due to their 
vacuolated cellular morphology and expression of genes specific to NCs [[52], [55], 
[56]]. For instance, the transcription factor T brachyury (T), a key regulator of 
notochord formation, is highly expressed in nearly every chordoma tumor [52], [55] 
and is critical for chordoma cell proliferation [57]. Additional notochordal markers 
expressed in the majority of chordomas include cytokeratin-8 (KRT8), cytokeratin-18 
(KRT18), cytokeratin-19 (KRT19), vimentin (VIM), CD24 molecule (CD24), and 
sonic hedgehog (SHH) [52], [55], [58]–[61]. What causes notochordal remnants, which 
generally disappear in humans with age, to become malignant is unknown and is 
actively being researched.  
 Currently, only five chordoma cell lines have been approved by the Chordoma 
Foundation: U-CH1, U-CH2, MUG-Chor1, JHC7, and UM-Chor1 [55]. Similar to 





notochordal genes [58], [62]–[64]. MUG-Chor1, the cell line we use in our studies, was 
derived from a sacral chordoma in a 57-year old female. MUG-Chor1 cells resemble 
NCs both morphologically and phenotypically, having a vacuolated cytoplasm and 
expressing T brachyury, cytokeratin, and vimentin proteins (Figure 2.3) [63]. Their 
notochordal phenotype and ability to be maintained in long-term cultures makes them 
an ideal NC source for in vitro assays.  
 
 
Figure 2.3: Characterization of the MUG-Chor1 cell line. (a) Histology of the primary tumor 
used to establish the MUG-Chor1 chordoma cell line reveals vacuolated tumor cells; (b) 
Immunohistochemistry (IHC) of the primary MUG-Chor1 tumor shows positive brachyury 
expression; IHC of MUG-Chor1 cells in culture shows positive (c) cytokeratin and (d) vimentin 






2.4 Treatment of Chordoma 
 The primary treatment option for patients living with chordoma is surgery. The 
goal of surgery is to obtain wide margins with a complete en bloc tumor resection, as 
intralesional resection is associated with an increased rate of recurrence [65]. However, 
achieving wide margins is not always possible due to chordomas proximity to vital 
structures and often times can lead to nerve sacrifice and motor dysfunction. If patients 
are not a candidate for surgery or if a complete resection was not achieved, radiation 
therapy is often administered. Because chordomas are resistant to radiation, large doses 
are required for treatment. To prevent damage to the surrounding tissue, conformal 
radiotherapy, such as proton beam therapy or radiosurgery, must be utilized. Radiation, 
especially near the skull and spine, is associated with numerous side effects and risks 
such as paralysis. Chordomas are also resistant to standard cytotoxic chemotherapy 
drugs such as cisplatin, doxorubicin, and paclitaxel [66]–[68]. While these cytotoxic 
drugs may be used to slow chordoma growth, they are ultimately an ineffective form 
of treatment. Due to the complications presented with treating chordoma, targeted 
therapies and immunotherapies are actively being researched. No drugs are currently 
approved by the FDA to treat chordoma; however, multiple clinical trials are open for 
various systemic therapies, including an anti-brachyury vaccine [69]. 
 
2.5 Vacuoles of Notochordal and Chordoma Cells 
 While cytosolic vacuoles are a defining feature of NCs and chordoma cells, 
their contents and function have not been conclusively determined. In developing 





essential role in embryonic axis elongation and spine morphogenesis [24], [27], [70]. 
The mechanical contribution of vacuoles to embryonic development is presumed to 
occur through the generation of turgor pressure, resulting in stiffening of the notochord. 
Recently, notochordal vacuoles have been suggested to be lysosome-related organelles, 
following the discovery of lysosomal-associated membrane protein 1 (LAMP1) on the 
vacuolar membrane of zebrafish NCs [24]. Although vacuoles of NCs are essential for 
embryonic development, the significance of cells maintaining vacuoles in the 
developed IVDs and in chordomas is unclear. Only one study was found to explore 
vacuolar function in mature NCs, which proposes vacuoles function as osmoresponsive 
organelles containing a low osmolality solution that can be used to regulate cell volume 
under hypotonic stress [71]. 
 
2.6 Vimentin and Cytokeratin Intermediate Filaments 
 IFs are an essential component of the cytoskeleton. The molecular building 
blocks of IFs are alpha-helical proteins, which form coiled-coil dimers. Dimers then 
stagger together to form tetramers, and groups of tetramers form unit-length filaments 
that join to form mature, ~10 nm wide IFs (Figure 2.4). In contrast to the consistent 
composition and expression of the other principal elements of the cytoskeleton, 
microtubules and actin microfilaments, many different types of IF proteins have been 
identified and their expression is typically cell-type specific. The different types of IF 
proteins have been categorized into six groups based off of their amino acid sequences. 
Types I and II are acidic and basic/ neutral cytokeratins, respectively. Acidic 





heterodimers, the basic building blocks of cytokeratin IFs, which are characteristically 
expressed in epithelial cells. Type III IF proteins include vimentin, and unlike 
cytokeratin IFs, vimentin IFs are composed of vimentin monomers. Vimentin IFs are 
characteristically expressed in mesenchymal cells. Types IV, V, and VI include 
neurofilament proteins, nuclear lamins, and nestin. This study focuses specifically on 
cytokeratin and vimentin IFs, which are co-expressed in NCs and chordoma cells. The 
most commonly expressed cytokeratin proteins in NCs and chordoma cells are those of 
the simple epithelium: cytokeratins 8, 18, and 19 [48], [72], [73]. Cytokeratins 8 and 
18 typically dimerize together, while cytokeratin-19 is unique in that it generally is not 
paired with a basic cytokeratin. 
 
 






 Until recently, the mechanical function of IFs has received little attention 
compared to actin microfilaments and microtubules, which have established roles in 
processes such as cell adhesion, migration, mechanotransduction, division, and 
(mediated by their specific motor proteins) intracellular organelle and protein transport 
[75]. The majority of functions associated with vimentin and cytokeratin IFs have been 
elucidated via genetic mutations of genes encoding cytokeratin and/or vimentin 
proteins, ultimately disrupting the IF network. Both cytokeratin and vimentin IFs have 
been found to contribute to cell stiffness, maintenance of cell structural integrity, and 
resistance to mechanical stress [3], [4], [8], [76]–[80]. For example, vimentin deficient 
fibroblasts were found to be significantly less stiff compared to wild-type cells and 
mutations in cytokeratins of keratinocytes resulted in reduced cell stiffness and 
increased (60%) cell deformability [3], [4], [78].  
 Vimentin and cytokeratin IFs have also been found to be involved in cell 
mechanotransduction [7], [8], [81], [82] and migration [10], [12], [83], [84]. In support 
of mechanosensing roles, decreasing vimentin and cytokeratin expression have both 
been observed to cause substrate stiffness dependent changes in cell spreading [7, p. 
18], [8]. Additionally,  the decoupling of vimentin and focal adhesions in fibroblasts 
resulted in decreased activation of the major mechanosensor molecule FAK [81]. For 
cell migration, a more established role has been identified for vimentin, rather than 
cytokeratin, IFs. The expression of vimentin IFs is often associated with increased cell 
migration and invasion [10], [12], [85], while the involvement of cytokeratin IFs in cell 






2.7 Methods for Studying Cellular Functions of Intermediate Filaments  
 Following their discovery, IF networks were initially presumed to be static and 
to primarily play a structural role [86]. However, IFs have since been identified as 
highly dynamic structures involved in cell migration and signaling pathways and 
mutations in IF proteins have been associated with various diseases [86]. Consequently, 
various methods have been established and optimized for further investigating the 
functional roles of IFs. Techniques typically rely on disruption of the IF network or 
silencing of genes encoding IF proteins. Microinjection of mimetic peptides, 
transfection of dominant-negative mutants, and treatment of cells with agents such as 
withaferin-A and acrylamide have all been used for dissembling and disrupting the 
organization of IF networks [87]–[89]. To eliminate off-target effects and more 
specifically analyze IF functions, strategies that knockdown or knockout IF protein 
expression are often employed. For instance, RNAi using small-interfering RNA 
(siRNA) or short hairpin RNA (shRNA) has shown success in decreasing both vimentin 
and cytokeratin protein expression in mammalian cells [11], [90]. Through RNAi, the 
roles of vimentin and cytokeratin IFs in process associated with cancer progression 
such as integrin signaling, cell migration, and cell invasion have been examined [9], 
[12]. Primary cells isolated from knockout mice, which do not express the IF protein 
of interest, are also commonly used for the analysis of IFs [78], [91]. 
 
2.8 RNA Interference with siRNA 
 RNAi is a commonly used technique for inhibiting gene expression. 





foreign nucleic acids into the genome. The mechanism is initiated when long double 
stranded RNA (dsRNA) is detected within the cell and cleaved by a ribonuclease 
(RNase) III enzyme called Dicer [92]. This produces siRNAs that are generally 21-23-
nucleotide (nt) duplexes with symmetric 2-3-nt 3’ overhangs [93] (Figure 2.5a). The 
siRNAs are incorporated into a multiprotein RNA-inducing silencing complex (RISC) 
and subsequently unwound. The now revealed anti-sense strand of the siRNA guides 
the RISC to the complementary mRNA sequence resulting in endonucleolytic cleavage 
of the mRNA (Figure 2.5b).  Following the discovery of RNAi in mammalian cells, 
this technique has been adopted and well established for regulating gene expression in 
vitro and RNAi-based therapeutics are actively being studied in clinical trials [94], [95]. 
In fact, the first ever siRNA-based drug (Onpattro) was just recently approved by the 
FDA for the treatment of peripheral nerve disease (polyneuropathy) caused by 
hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. Because the 
introduction of long dsRNA into mammalian cells induces an adverse anti-viral 








Figure 2.5: Short interfering (si)RNA structure and the RNAi pathway. (a) siRNAs are 21-23-
nt duplexes with 5’ phosphorylated ends and 2-3-nt 3’ overhangs; (b) Schematic of the RNAi 
pathway. siRNAs are produced through cleavage of long dsRNA and incorporated into a RISC. 
Once unwound, the anti-sense strand of the siRNA guides RISC to complementary mRNA for 






2.9 Co-expression of Vimentin and Cytokeratin  
 Vimentin and cytokeratin co-expression is commonly found in cells with an 
epithelial origin and a mesenchymal differentiation or vice versa, cancer cells, and cells 
of developing tissues  [17], [48], [96]–[98]. Both NCs of the developing notochord and 
chordoma cells are consistent with these classifications. The co-expression of vimentin 
and cytokeratin is also common in cells that are exposed to a fluid/semi-fluid 
environment with low protein content [48], [99]. These conditions are true of the 
immature NP, where healthy tissue has a high (~80%) water content [100], [101]. While 
common environmental and cellular conditions have been identified, the functional 
significance for cells to co-express vimentin and cytokeratin IFs is not understood. In 
certain cancers, the co-expression of vimentin and cytokeratin IFs may encourage a 
more invasive and metastatic cell phenotype [9], [16], [17]. However, the contribution 
of cytokeratin IFs to the migration of cells co-expressing cytokeratin and vimentin 
appears to be cell-type specific, as conflicting findings have been reported following 
the manipulation of cytokeratin expression [9], [11], [84], [102]. 
 
2.10 Intermediate Filaments and Cancer 
 Cancer cells commonly co-express vimentin and cytokeratin IFs, suggesting a 
dedifferentiated phenotype, which is thought to promote cell invasion and cancer 
metastasis [17]. The epithelial-mesenchymal transition, characterized by increased 
vimentin expression, is typically associated with increased metastasis and a poor 
prognosis. In both cancerous and non-cancerous cells, knockdown of vimentin 





Similarly, the overexpression of vimentin has been linked to tumor metastasis in a 
variety of cancers including melanoma [15], breast cancer [17], prostate carcinoma 
[19], and hepatocellular carcinoma [18]. Because of the positive correlation between 
vimentin expression and metastasis, it is unsurprising that vimentin is associated with 
a poor prognosis. For instance, vimentin-positive basal-like breast cancer samples were 
significantly associated with poorer recurrence-free survival or overall survival [104].  
 In contrast to the consistent evidence supporting the role of vimentin in cancer 
cell migration and its association with a poor cancer prognosis, contradicting results 
have been reported for the role of cytokeratin IFs in cancer. In non-small cell lung 
cancer and oral squamous cell carcinoma, knockdown of cytokeratins 8 and 18 
decreased cell migration and invasion [9], [84]. The overexpression of cytokeratins 8 
and 18 has also been associated with increased migration in melanoma cells [16]. On 
the other hand, increased expression of cytokeratin 18 reduced cell invasion in breast 
cancer cells [102] and decreased expression of cytokeratins 8 and 18 increased cell 
migration and invasion in liver hepatocellular carcinoma cells [83]. The effects of 
altering cytokeratin expression on cell migration may be attributed to resulting changes 
in vimentin expression [102]. It is also possible that cytokeratin IFs play a direct role 
in cell migration, as vimentin expression was unaffected in non-small cell lung cancer 
cells shown to have decreased cell migration following cytokeratin 18 knockdown [84].  
 The relationship between cytokeratin expression and cancer prognosis also 
appears to be cancer-type specific. High cytokeratin 18 expression has been correlated 
with advanced stages of cancer and poor prognosis in non-small cell lung cancer, 





[84], [105]–[107]. The opposite trend was observed in breast and colorectal cancers, 
where low cytokeratin 8 and 18 expression has been associated with a poor prognosis 
[108], [109].  
 Interestingly, IFs have also been suggested to be involved in cell sensitivity to 
cytotoxic chemotherapy agents. EMT suppression, associated with decreased vimentin 
expression, has been found to increase the sensitivity of non-small cell lung cancer and 
gastric cancer cells to cisplatin [20, p. 30], [22], a cytotoxic agent that initiates 
apoptosis through its binding with DNA. Knockdown of cytokeratins 8 and 18 has 
produced similar results, increasing the sensitivity of epithelial cancer and 
nasopharyngeal carcinoma cells to cisplatin [21], [83] and non-small cell lung cancer 
cells to paclitaxel [84], a cytotoxic drug that stabilizes microtubules, thereby inhibiting 
cell division. The mechanism in which disrupting IFs sensitizes cells to cytotoxic 
chemotherapeutics is currently unknown. 
 
2.11 Biomechanics of Cancer 
 Abnormal changes in the mechanical properties of tissues are associated with 
diseases such as cancer. For example, tumors tend to be stiffer than healthy tissue and 
tissue stiffness is often exploited for cancer screening. For breast cancer, the tumor 
tissue can be ten times stiffer than normal tissue [110]. Increased tissue stiffness can 
partly be attributed to lysyl oxidase (LOX) overexpression, which promotes cross 
linking of ECM components such as collagen [111]. Further, data suggests that 
overexpression of LOX and subsequent ECM stiffening regulates angiogenesis, a key 





exertion of traction forces, cells are able to sense the mechanical properties of the ECM. 
As a result, cell behaviors, such as proliferation and migration, are affected by changes 
to the ECM. For instance, increased ECM stiffness can stimulate integrin signaling and 
as a result promote cell survival and proliferation [14], [113]. The relationship between 
ECM rigidity and cancer behavior at the molecular level is unclear; however, studies 
have shown that increased ECM stiffness is capable of promoting a malignant cell 
phenotype with increased chemoresistance [13], [14]. Mechanical cues have also 
shown promise as cancer biomarkers, as cell deformability and traction forces are found 





Chapter 3: The Roles of Vimentin and Cytokeratin-8 




 The embryonic notochord consists of highly vacuolated cells surrounded by a 
basement membrane sheath [24]–[27]. Radial constriction provided by the outer 
membrane sheath on osmotically swelling vacuoles of the inner cells is essential for 
driving elongation of the embryo [24], [26], [27]. With development of the vertebral 
column, notochordal remnants become segmented between vertebral bodies forming 
the immature NP [32], [33]. In some vertebrates such as pigs, rabbits, rats, and mice 
cells of presumed notochordal origin (NCs) remain in the NP throughout life [33], [34]. 
However, as humans age the majority of NCs give way to smaller, more chondrocyte-
like, mature NP cells [35]–[37]. This cellular transition coincides with changes in the 
ECM such as decreases in water and proteoglycan content [44], [119], [100], [120], 
impairing NP function and increasing the risk of disc degeneration [121], [122]. 
 In certain cases, notochordal remnants may develop into a tumor called 
chordoma. Because of their proximity to the brain stem and spinal cord, chordomas are 
difficult to remove surgically and treatment with high doses of radiation therapy is not 
always possible. Additionally, chordomas are resistant to conventional cytotoxic 
chemotherapy drugs. Consequently, chordomas are often associated with high 
                                                 
 This chapter was adapted from Resutek, L and Hsieh AH. The vacuolated morphology of chordoma 





recurrence rates and a poor prognosis. An improved understanding of the NC cell 
phenotype is essential for the development of treatments for both disc degeneration and 
chordoma.  
 NCs and chordoma cells are characterized by their large size, expression of 
phenotypic genes, organization in dense cell clusters, and unique cytosolic vacuoles. In 
Xenopus and zebrafish embryos, notochord vacuoles have been found to be essential 
for elongation and morphogenesis of the developing spine [24], [27], [70]. Although 
vacuoles of embryonic NCs are essential for development, the significance of cells 
maintaining vacuoles in the developed IVD and in chordomas is unclear, but has 
remained an area of particular interest [123]. Genes often used to identify NCs and 
chordoma cells include brachyury (T), SHH, N-cadherin, and cytokeratin-8, -18, and -
19 [42], [40], [43]–[47]. Brachyury and SHH play key roles in embryonic development, 
but in developed tissues their overexpression has been associated with tumor formation 
and progression [124], [125]. Increased expression of brachyury, SHH, and N-cadherin 
have all been connected to EMT, characterized by increased vimentin expression 
[125]–[130]. Therefore, the expression of these phenotypic genes may be dependent on 
IF protein expression. 
 Similar to other cells of developing tissues and cancer cells, NCs and chordoma 
cells co-express cytokeratin and vimentin IFs [44], [48].  In contrast, mature NP cells 
tend to express only vimentin IFs [44]. Vimentin IFs are composed of vimentin 
monomers and cytokeratin IFs are composed of acidic, type I cytokeratins (9-20) and 
basic type II cytokeratins (1-8) heterodimers. Focusing on cytokeratins specific to NCs, 





suggested to be capable of substituting for cytokeratin-18 [131]. Individually, vimentin 
and cytokeratin IFs have been shown to be involved in cell stiffness [3], [4], [8], [78], 
adhesions [103], [132], [133], and response to mechanical stimuli [7], [81]. They have 
also been associated with the stabilization and transport of vacuoles, vesicles, and 
granules [134]–[137]. In NCs, IFs were observed to surround vacuoles, suggesting a 
structurally supportive role [25]. However, the involvement of vimentin and 
cytokeratin IFs in NC vacuolation, either individually or in tandem, is unknown.  
 Due to the concomitant loss of cytokeratin expression and vacuoles in mature 
NP cells, we sought to investigate the potential relationship between cytokeratin IFs, 
specifically those containing cytokeratin-8 proteins, and the vacuoles of NCs. Using a 
human chordoma cell line (MUG-Chor1), we examined the organization of the 
cytoskeleton in relation to vacuoles and the effect of chemically disrupting IFs, F-actin, 
and microtubules on the cytosolic vacuoles. We then focused on cytokeratin-8 and 
vimentin IFs and their individual roles in the existence of vacuoles, utilizing siRNA-
mediated RNAi for the knockdown of cytokeratin-8 and vimentin expression. We 
found that both chemical disruption of IF networks and knockdown of cytokeratin-8 
expression were associated with dramatic reduction of cellular vacuolation. Decreased 
cytokeratin-8 and vimentin expression, in addition to subsequent changes in 






3.2 Materials and Methods 
3.2.1 Cell Culture 
 MUG-Chor1 chordoma cells were obtained from ATCC® (ATCC Cat# CRL-
3219, RRID:CVCL_9277) and cultured in Iscove's Modified Dulbecco's Medium: 
Roswell Park Memorial Institute 1640 Medium (4:1) (Gibco/Thermo Fisher Scientific, 
Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) 
(Gibco/Thermo Fisher) and 1% Penicillin-Streptomycin (Gibco/Thermo Fisher). Cells 
were expanded on tissue culture-treated polystyrene (TCTP) and plated on adsorbed 
(50 μg/ml) rat tail type I collagen (Advanced BioMatrix, Carlsbad, CA, USA), as 
recommended by ATCC®, for all subsequent experiments. Complete media exchange 
was completed every 2-3 days and cells were cultured at 37°C, 5% CO2. 
 
3.2.2 Cytoskeletal Disruption 
 Cells cultured on collagen-coated glass were treated with chordoma media 
containing 1 μM cytochalasin-D [138] (Sigma-Aldrich, St. Louis, MO, USA), 5 μM 
nocodazole [139] (Sigma-Aldrich), or 40 mM acrylamide [140], [141] (Thermo Fisher) 
to disrupt F-actin, microtubules, or IFs, respectively. Cells were incubated with 
cytochalasin-D and nocodazole for 1h and acrylamide for 3.5h at 37°C, 5% CO2. 
Disruption of targeted cytoskeletal elements was visualized with immunostaining and 
confocal microscopy. Cells were stained with calcein AM (Invitrogen/Thermo Fisher) 






3.2.3 Transfection of siRNA 
 For all transfections, chordoma cells were plated on adsorbed type I collagen in 
6-well plates at a density of 10,000 cells/ cm2. Twenty-four hours after plating, cells 
were transfected with Silencer Select Pre-designed siRNA (Ambion/Thermo Fisher) 
targeting either KRT8 (s7970), VIM (s14798), or Silencer Select Negative Control No. 
1 siRNA (Ambion/Thermo Fisher) using Lipofectamine 2000 (Invitrogen/Thermo 
Fisher). Cells were incubated with siRNA-lipofectamine complexes (300pmol siRNA: 
12.5ul Lipofectamine per well) for 24h. Six days after transfection, cells were 
processed for analysis of vacuoles, cell clustering, cytoskeletal organization, gene 
expression, or protein content. Due to changes in cell behavior as a result of 
transfection, non-transfected chordoma cells were excluded from analyses. 
 
3.2.4 Immunostaining and Fluorescence Microscopy 
 To observe cytoskeletal proteins, cells were fixed with 4% paraformaldehyde 
(PFA) and permeabilized using 0.1% Triton X-100. Cells were labelled with rabbit IgG 
anti--tubulin polyclonal (Abcam, Cat# ab15568, RRID:AB_2210952), rabbit IgG 
anti-vimentin [SP20] (Thermo Fisher Scientific, Cat# MA5-16409 , AB_2537928), or 
mouse IgG1 anti-cytokeratin-8 [M20] (Abcam, Cat# ab9023 RRID:AB_306948) 
antibodies. A biotinylated (anti-rabbit IgG) secondary antibody (Vector Laboratories, 
Cat# BA-1000, RRID:AB_2313606) was used in combination with Fluorescein- or 
Texas Red-labelled streptavidin (Vector Laboratories) to visualize -tubulin and 
vimentin. An Alexa Fluor 594-conjugated (anti-mouse IgG) secondary antibody 





cytokeratin-8. Cells were stained with Alexa Fluor 594 Phalloidin (Invitrogen/Thermo 
Fisher Scientific) to visualize F-actin, and DAPI (Invitrogen/Thermo Fisher Scientific) 
was used as a nuclear counterstain. All images were captured with a Nipkow (spinning) 
disk-equipped Olympus IX81 microscope. Confocal fluorescence Z-stacks (1 μm 
slices) were taken with the spinning disk and projected into single images.  
 
3.2.5 Gene Expression 
 RNA isolation was performed using phenol-chloroform extraction. Cell 
monolayers were lysed with TRIzol (Ambion/Thermo Fisher Scientific) and RNA was 
separated and precipitated from the resulting lysate using chloroform and isopropanol. 
RNA samples were reverse transcribed, and underwent qRT-PCR (MyiQ System, 
BioRad) using SsoFast EvaGreen Supermix (BioRad, Hercules, CA, USA) to quantify 
expression of VIM, KRT8, T, SHH, CDH2, and 18S (Table 3.1). Relative quantitation 
of qRT-PCR data was performed using the ΔΔCt method with 18S as a housekeeping 
gene. Briefly, ΔCt values were computed by subtracting Ct values of the 18S control 
gene from those of each gene of interest (i.e., ∆𝐶𝑡 𝑆𝐻𝐻 =  𝐶𝑡 𝑆𝐻𝐻 − 𝐶𝑡 18𝑆). For each 
gene of interest, ΔΔCt values were computed by subtracting ΔCt values of the reference 
sample (e.g. cells transfected with negative control siRNA), from ΔCt values of cells 
transfected with siRNA targeting either VIM or KRT8 (∆∆𝐶𝑡 𝑆𝐻𝐻;𝑉𝐼𝑀 𝑠𝑖𝑅𝑁𝐴 =
 ∆𝐶𝑡 𝑆𝐻𝐻;𝑉𝐼𝑀 𝑠𝑖𝑅𝑁𝐴 − ∆𝐶𝑡 𝑆𝐻𝐻;𝑁𝐶 𝑠𝑖𝑅𝑁𝐴). Using ΔΔCt values, relative changes in mRNA 
levels (fold difference) were expressed through the exponential relation: 2-ΔΔCt. 
Technical replicates for each sample, along with appropriate no RT and no template 
controls, were performed in triplicate. Data collected over three independent cell 





range of the fold difference, which incorporates the standard deviation of the ΔΔCt 
value [142], [143]. 
 




5’-AAACGGCTACCACATCCAAG-3’      
5’-CCTCCAATGGATCCTCGTTA-3’ 
NR_146119 


















5’-TCAGGCGTCTGTAGAGGCTT-3’      
5’-ATGCACATCCTTCGATAAGACTG-3’    
NM_001792 
Table 3.1: Sequences of primers used for qRT-PCR 
 
3.2.6 Western Blotting 
 For protein extraction, cells were detached from culture surfaces using 0.25% 
trypsin-EDTA (Gibco/Thermo Fisher) and re-suspended in a lysis buffer (50 mM 





pyrophosphate, 10% glycerin) supplemented with a 1:100 concentration of protease 
inhibitor cocktail (Thermo Fisher). Protein concentrations were determined using a 
sample of the protein extract in a modified Lowry assay with a Folin-Phenol color 
reaction detected by a ND-1000 Spectrophotometer. Remaining extracts were mixed 
(1:1) with a loading buffer (13% (v/v) Tris-HCl, 20% (v/v) glycerol, 4.6% (w/v) SDS, 
0.02% (w/v) bromophenol blue, 200 mM dithiothreitol) for subsequent SDS-PAGE. 
For SDS-PAGE, 8µg of protein per sample was loaded into pre-cast Criterion Tris-HCl 
gels (BioRad). Proteins were then electrophoretically transferred to a polyvinylidene 
fluoride membrane and detected using rabbit IgG anti-vimentin polyclonal (Abcam, 
Cat# ab45939, RRID:AB_2257290) and mouse IgG1 anti-cytokeratin-8 [M20] 
(Abcam) antibodies in combination with Vectastain ABC-AmP for chromogenic 
detection. Detection of GAPDH using a rabbit IgG anti-GAPDH [EPR16884] (Abcam, 
Cat# ab181603, RRID:AB_2687666) antibody was used as a loading control. Semi-
quantitative analysis was performed using ImageJ (https://imagej.nih.gov/ij/,  
RRID:SCR_003070) to determine vimentin and cytokeratin-8 band intensities 
normalized to GAPDH.  Protein expression levels are reported as experimental relative 
to cells transfected with negative control siRNA ± SEM. 
 
3.2.7 Vacuole Analysis  
 To determine the effect of cytoskeletal disruption on the vacuolar morphology 
of chordoma cells, phase-contrast images of the same cells before and after cytoskeletal 
disruption were captured. Cells were stained immediately after cytoskeletal disruption 





images. Control cells were imaged before and 3.5h after the addition of untreated 
medium. For each treatment group, phase-contrast images were used to count the 
number of vacuoles in the same cells before and after treatment. For each treatment, 
three independent experiments were performed and between 53-72 cells/cell clusters 
were observed.  Data are reported as the average number of vacuoles per sample (cell 
or cell cluster) ± SEM. Using these data, the average percent vacuole loss per sample 
was calculated and reported as the average ± SEM.  
 To further examine the relationship between vimentin and cytokeratin-8 IFs and 
cytosolic vacuoles, the number of vacuoles within siRNA-mediated vimentin and 
cytokeratin-8 knockdown cells was compared to that of cells transfected with negative 
control siRNA. Six days after transfection, cells were stained with calcein AM 
(Invitrogen/Thermo Fisher Scientific), a live-cell dye that does not permeate into the 
vacuole lumen (Figure 3.1a), to visualize vacuoles and the nuclear counterstain Hoechst 
33342 (Invitrogen/Thermo Fisher Scientific). For each treatment, three independent 
cell transfection experiments (n=3) were performed. Each sample was imaged under 
fluorescence microscopy (100x magnification), five fields of view captured, and the 
number of vacuoles and cells counted across these five fields of view to obtain the 
average vacuoles per cell in each experiment. Data are reported as the average ± SEM 
across the three experimental samples. Additionally, we sought to characterize the 
distribution of vacuoles per cell for each of the treatments. To do this, we utilized the 
same images to identify single cells transfected with negative control siRNA (n= 276), 





transfection group, frequency distributions were obtained by normalizing these data to 
the number of cells analyzed in each group.   
 
3.2.8 Cell Clustering 
 To determine the necessity of vimentin and cytokeratin IFs in cell clustering, 
knockdown cells were cultured on basement membrane extract (BME) gel substrates, 
which have previously been shown to promote clustering of NCs [144]. BME is 
extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma tumor, which 
contains high concentrations of laminin-111 (~60%) and type IV collagen (~30%) 
[145]. Thin BME gels were created by dispensing 122.5 µl of unpolymerized BME 
(Trevigen, Gaithersburg, MD, USA) into 14 mm diameter glass-bottom wells and 
incubating for 30 minutes at 37C. Knockdown cells were seeded onto BME gels at a 
density of ~32,500 cells/cm2 (50,000 cells/gel) and cultured for 48 hours. Cells were 
stained with calcein AM (Invitrogen/Thermo Fisher Scientific) and the nuclear 
counterstain Hoechst 33342 (Invitrogen/Thermo Fisher Scientific) to observe cell 
organization. Samples were imaged under phase-contrast and fluorescence microscopy 
(100x magnification). 
 
3.2.9 Statistical Analysis  
 Statistical analyses were completed using Microsoft Excel or SPSS 
(http://www-03.ibm.com/software/products/en/spss-statistics/,  RRID:SCR_002865) . 
The non-parametric Wilcoxon test for matched samples was used to compare the 





nocodazole, or cytochalasin-D (𝛼 = 0.001). Kruskal-Wallis followed by Mann-
Whitney U tests for independent samples were utilized to compare percent vacuoles 
lost among groups subjected to chemical disruption (𝛼 = 0.001). A one-sample t-test 
was used to compare the relative expression of cytokeratin-8 and vimentin, as measured 
by Western blot, in siVIM- and siKRT8-cells to that of siNEG-cells (𝛼 = 0.05). Mann-
Whitney U tests were used to compare gene expression of siVIM- and siKRT8-cells to 
siNEG-cells (𝛼 = 0.05). For siRNA treated cells, after confirming normality of 
residuals for the data, one-way analysis of variance (ANOVA) followed by Tukey’s 
HSD post hoc tests were used to compare average number of vacuoles per cell between 
transfection groups (𝛼 = 0.05). The Kolmogorov-Smirnov Test was used to compare 




3.3.1 Cytokeratin-8 Intermediate Filaments Organize around Cytosolic Vacuoles in 
Chordoma Cells 
 To gain a better understanding of the structural relationship between the 
cytoskeleton and cytosolic vacuoles of chordoma cells, localization of F-actin, 
microtubules, vimentin, and cytokeratin-8 IFs was examined relative to vacuole 
positions. Similar to NCs derived from non-chondrodystrophoid dogs [71], we 
confirmed that calcein AM fluorescence was consistently excluded from chordoma cell 
vacuoles as clearly evident from comparing bright field and fluorescence images of 





vacuoles in all subsequent fluorescence labeling procedures. Fluorescence 
visualization of calcein AM and labelled cytoskeletal proteins of the same cells 
revealed that only cytokeratin-8 IFs organize immediately around vacuoles (Figure 
3.1b). This peri-vacuolar relationship was not observed for vimentin IFs, F-actin, or 







Figure 3.1: Organization of vacuoles and the cytoskeleton in chordoma cells cultured in 
monolayer. (a) Bright field and fluorescence images of cells stained with calcein AM (green) 
for the identification of vacuoles. Scale bars: 20 µm; (b) Representative confocal images of 
chordoma cells stained with calcein AM (green) and labeled for cytoskeletal proteins (red). 
Scale bars: 10 µm.  
 
 
3.3.2 Disruption of the Cytoskeleton, Primarily Intermediate Filaments, Decreases the 
Number of Cytosolic Vacuoles in Chordoma Cells 
 To elucidate any potential structural relationship between the cytoskeleton and 
cytosolic vacuoles of chordoma cells, we quantified vacuole number before and after 
chemical disruption of IFs, F-actin, and microtubules. For these cells, vimentin and 
cytokeratin-8 IFs were successfully disrupted with 40 mM acrylamide, F-actin with 1 
µM cytochalasin-D, and microtubules with 5 µM nocodazole (Figure 3.2b). Treatment 
of cells with acrylamide, cytochalasin-D, and nocodazole all resulted in a significant 
(p< 0.001) loss of vacuoles compared with images of the same cells prior to treatment, 
whereas control cells were not markedly affected (Figure 3.3a, b). However, vacuole 
loss was the greatest in cells treated with acrylamide (Figure 3.3c). The percent vacuole 
loss caused by acrylamide was significantly (p< 0.001) larger than that caused by 
cytochalasin-D or nocodazole. Both acrylamide and cytochalasin-D treated cells 
exhibited significantly (p< 0.001) higher percent vacuole loss than control cells. In 
addition to a significant reduction in the number of vacuoles, disruption of IFs with 
acrylamide appeared to affect vacuole morphology, where remaining vacuoles were 
observed to be less circular than those of control cells (Figure 3.3a). This qualitative 
effect on vacuole morphology was not observed in cytochalasin-D or nocodazole 






Figure 3.2: Chemical disruption of the cytoskeleton in chordoma cells. (a) Live-dead stain of 
chordoma cells after cytoskeletal disruption with 40 mM acrylamide for 3.5h, 5 µM nocodazole 
for 1h, or 1 µM cytochalasin-D for 1h. ‘Untreated Control’ cells were not incubated with 
cytoskeleton disrupting agents and ‘Dead Control’ cells were killed with 70% ethanol. Calcein-
AM (green) and ethidium homodimer-1 (red). Scale bars: 50 µm; (b) Representative confocal 





nocodazole for 1h, or 1 µM cytochalasin-D for 1h. Intermediate filaments: vimentin (green) 
and cytokeratin-8 (red). Scale bars: 10 µm. 
 
 
Figure 3.3: The effect of chemical disruption of the cytoskeleton in chordoma cells on 
cytosolic vacuoles. (a) Representative bright field images of chordoma cells before and after 
cytoskeletal disruption. Live-dead stain of cells after cytoskeletal disruption, calcein-AM 
(green) and ethidium homodimer-1 (red). Scale bars: 16 µm; (b) The average number of 





cytochalasin-D (n=59) for 1h, 5 µM nocodazole (n=72) for 1h, or control medium (n=57) for 
3.5h reported as average ± SEM. *p< 0.001, comparing before and after treatment; (c) The 
average percent of vacuoles lost per sample following treatment with 40 mM acrylamide 
(n=53) for 3.5h, 1 µM cytochalasin-D (n=59) for 1h, 5 µM nocodazole (n=72) for 1h, or control 
medium (n=57) for 3.5h reported as average ± SEM. *p< 0.001, relative to control, 
cytochalasin-D, and nocodazole; +p< 0.001, relative to control. 
 
3.3.3 siRNA Mediated Knockdown of Vimentin and Cytokeratin-8 Expression in 
Chordoma Cells 
 When cells were examined six days after transfection, chordoma cells 
transfected with siRNA targeting VIM (siVIM) and KRT8 (siKRT8) exhibited 
significant decreases in their respective expression of vimentin and cytokeratin-8. 
Compared to cells transfected with negative control siRNA (siNEG), siVIM-
transfected cells exhibited a 41% decrease in vimentin and siKRT8-transfected cells 
exhibited a 26% decrease in cytokeratin-8, as observed by Western blotting (Figure 
3.4a). In addition to decreased expression of cytokeratin-8, siKRT8-transfected cells 
exhibited an almost equivalent decrease in vimentin. The reciprocal off target effect 
was less dramatic for siVIM-transfected cells, which only exhibited a slight decrease 
in cytokeratin-8 (~2%). Observed decreases in vimentin and cytokeratin-8 proteins in 
siVIM- and siKRT8-transfected cells were corroborated by immunofluorescence 
(Figure 3.4b). Assessment by qRT-PCR showed that siVIM- and siKRT8-transfected 
cells possessed significant decreases in respective VIM and KRT8 expression (Figure 
3.6a). Curiously, we found that in contrast to Western blot analysis data, qRT-PCR 
indicated increased gene expression of the non-targeted IF in siVIM- and siKRT8-






Figure 3.4: Characterization of cytokeratin-8 and vimentin knockdown in chordoma cells six 
days after transfection with siRNA. (a) Western blot of siKRT8- and siVIM-transfected cells 
analyzed relative to siNEG-transfected cells. Data is reported as the average ± SEM. *p< 0.05, 
relative to siNEG-cells. KRT8 and VIM band intensities normalized to GAPDH. ‘Control’ is a 





fluorescence images of siNEG-, siKRT8- and siVIM-transfected cells. Cytokeratin-8 (red) and 
vimentin (green). Scale bars: 50 µm. 
 
 
3.3.4 Cytokeratin-8 Knockdown, but not Vimentin Knockdown, Leads to Reduction in 
Cytosolic Vacuoles in Chordoma Cells 
 To determine whether or not vimentin and cytokeratin-8 IFs each play a 
functional role in supporting vacuole presence in chordoma cells, we compared the 
number of vacuoles in cultures treated with siVIM, siKRT8, and siNEG (Figure 3.5a). 
Analyses of calcein AM fluorescence images revealed that siKRT8-cells possessed 
significantly (p< 0.001) fewer vacuoles per cell compared to siVIM- and siNEG-cells 
(Figure 3.5b). There was no significant difference between siVIM- and siNEG-cells 
(p=0.081). The distributions of vacuole number per cell was also significantly (p< 
0.001) different for siKRT8-cells compared to siVIM- and siNEG-cells (Figure 3.5c). 
In contrast to siKRT8-cells, which more frequently had 0-1 vacuoles per cell, siVIM- 






Figure 3.5: The effect of vimentin and cytokeratin-8 knockdown on the number of cytosolic 
vacuoles in chordoma cells. (a) Representative bright field and fluorescence images of siNEG-
, siVIM-, and siKRT8-cells stained with calcein AM (green) and Hoechst 33342 (blue). Scale 
bars: 25 µm; (b) The average number of vacuoles per cell in siNEG-, siVIM-, and siKRT8-
cells reported as average ± SEM. *p< 0.001, relative to siNEG- and siVIM-cells; (c) The 
distribution of the number of vacuoles per cell in siNEG- (n=276), siVIM- (n=236), and 
siKRT8-cells (n=315) normalized to the number of cells analyzed. *p< 0.001, relative to 







3.3.5 Knockdown of Cytokeratin-8 and Vimentin in Chordoma Cells does not 
Immediately Affect Gene Expression or Cell Clustering  
 The effects of cytokeratin-8 and vimentin knockdown on the NC and chordoma 
cell phenotype were further investigated through gene expression and cell clustering 
analysis. Despite the reduction of cytosolic vacuoles in siKRT8-cells, cytokeratin-8 
knockdown did not significantly alter gene expression of the phenotypic cell markers 
T, SHH, and CDH2 (Figure 3.6a). Expression of these characteristic genes were also 
not altered in siVIM-cells (Figure 3.6a).  Additionally, characteristic cell clustering on 







Figure 3.6: The effect of vimentin and cytokeratin-8 knockdown in chordoma cells on gene 
expression of phenotypic markers and cell clustering. (a) Gene expression of siKRT8- and 
siVIM-transfected cells analyzed relative to siNEG-transfected cells. *p<0.05, relative to 
siNEG-cells; (b) Representative bright field and fluorescence images of cells stained with 
calcein AM (green) and Hoechst 33342 (blue). Scale bars: 50 µm. 
 
3.4 Discussion 
 Results of this study show that IFs play a significantly greater role in supporting 
cytosolic vacuoles in chordoma cells than microfilaments and microtubules. Further 
parsing the specific involvement of different types of IFs indicated that cytokeratin-8 





are consistent with prior observations of age-associated morphologic and coincident 
phenotypic cytoskeletal changes observed in cells populating the NP. NCs, of the 
immature NP and chordoma, are characterized by their vacuolated cytoplasm and co-
expression of cytokeratin and vimentin IFs [32], [33], [40], [44], [47], [48], while 
smaller, more chondrocyte-like cells populating the adult NP are not vacuolated and 
typically only express vimentin IFs [35]–[37], [44]. 
 While the formation of cytosolic vacuoles is a defining feature of NC 
differentiation, the contents and function of these vacuoles in mature, mammalian NCs 
have not been conclusively established. In developing Xenopus and zebrafish embryos, 
notochord vacuoles have been found to be required for elongation of the embryonic 
body axis and play an active role in spine morphogenesis, presumably serving to 
generate turgor for stiffening the notochord [24], [27], [70]. Cell-matrix interactions 
and cell motility patterns have been shown to be centrally important to the notochordal 
vacuolation process [146], [147]. Recently, it has been shown that LAMP1 can be 
found on the vacuolar membrane of zebrafish NCs and that H+-ATPase is required for 
vacuole integrity; yet, the vacuole lumen itself is not acidic [24]. Taken together, these 
observations suggest that notochordal vacuoles are unique lysosome-related organelles 
unlike others that have been characterized [148]. Interestingly, the only other known 
vacuolar organelle that utilizes H+-ATPase for anything besides acidification are 
contractile vacuoles, which are used for osmoregulation and fluid segregation, in 
protists [149]–[151]. Although vacuoles of embryonic NCs are essential for 
development, the significance of cells maintaining vacuoles in the developed IVDs and 





study that explores vacuolar function in mature NCs proposes vacuoles to be 
osmoresponsive organelles containing low osmolality solution that can be used to 
regulate cell volume under hypotonic stress [71]. Similar to their role in embryonic 
NCs, vacuoles within chordoma and the developed NP may serve some sort of 
mechanobiological function.  
 Previous studies have implicated the cytoskeleton in the formation, localization, 
transport, and structural stabilization of vacuoles and vacuole-like structures such as 
vesicles and granules [134]–[137], [152]. However, the role of IFs in supporting 
vacuoles of NCs and chordoma cells has not been thoroughly examined. To investigate 
this relationship, we used a human chordoma cell line (MUG-Chor1), which has 
previously been shown to possess a vacuolated morphology and co-express vimentin 
and cytokeratin IFs [63]. The peri-vacuolar network of cytokeratin-8 IFs we observed 
in chordoma cells suggest that they are structurally involved in maintaining the 
vacuoles. This finding is consistent with previous studies of the hagfish notochord, 
where IFs were observed to organize around vacuoles [25]. Contrary to previous studies 
of canine NCs, we did not observe F-actin networks around vacuoles [40]. We also did 
not observe networks of microtubules or vimentin IFs to surround vacuoles.  
 To elucidate the relationship between the cytoskeleton and cytosolic vacuoles 
further, cells were treated with cytoskeleton disrupting agents targeting IFs, F-actin, 
and microtubules. The significant decrease in the number of vacuoles per cell as a result 
of disrupting IFs with acrylamide, F-actin with cytochalasin-D, and microtubules with 
nocodazole confirmed the involvement of the cytoskeleton. Because cells with 





more prominent role in supporting vacuoles than F-actin and microtubules. In addition 
to the significant decrease in the number of vacuoles in cells with disrupted IFs, 
remaining vacuoles appeared collapsed and tended be less circular than controls. 
Although the number of vacuoles significantly decreased in cells with disrupted F-actin 
and microtubules, the reduction was far less pronounced, and remaining vacuoles 
appeared to maintain their circular shape. Thus, it may be that the decrease in the 
number of vacuoles in cells with disrupted F-actin and microtubules is an indirect effect 
of chemical disruption of these targeted elements caused by accompanying changes 
such as cell shape and size. Since we have not analyzed the off-target effects of 
acrylamide, cytochalasin-D, and nocodazole, it is also possible that the application of 
these agents affects non-targeted cytoskeletal elements [140], [153]–[156]. 
 Based on the significant effect of IF disruption on vacuoles, we sought to target 
IFs containing vimentin and cytokeratin-8 more specifically using siRNA-mediated 
RNAi. In agreement with our observations of cytokeratin-8 IFs surrounding vacuoles, 
chordoma cells with reduced cytokeratin-8 expression (siKRT8-cells) exhibited fewer 
vacuoles per cell compared to controls (siNEG-cells) and cells with reduced vimentin 
expression (siVIM-cells). Because siKRT8-cells exhibited decreases in both 
cytokeratin-8 and vimentin expression, it is possible that co-expression of cytokeratin 
and vimentin IFs is involved in the vacuolated cytoplasm characteristic of chordoma 
cells. However, the fact that siKRT8-cells possessed significantly fewer vacuoles than 
siVIM-cells, which exhibited only decreased vimentin expression, suggests that 
cytokeratin-8 IFs plays a dominant role in the vacuolation of chordoma cells. As both 





mature NP cells [33], [40], [42], [44], [45], the decrease in cytokeratin expression 
observed with NP maturation may potentially be a factor responsible for the loss of a 
vacuolated cytoplasm.  
 Another possible interpretation of our data is that cytokeratin-8 IFs are 
necessary for vacuole formation. Cells transfected with our negative control siNEG 
using Lipofectamine2000 appeared to contain more vacuoles following a week of 
subconfluent culture compared to untreated control cells. In untreated chordoma cells, 
we have observed similar increases in vacuole number after cultures reach confluence. 
If vacuolation is enhanced by transfection, the reduced number of vacuoles observed 
in siKRT8-cells compared to siVIM- and siNEG-cells may be the result of inhibited 
vacuole formation. Because knockdown of IFs with RNAi (in contrast to chemical 
disruption) is a gradual process, we could not examine the same cells before and after 
IF protein knockdown and therefore were unable determine the change in the number 
of vacuoles for a particular cell/ cell cluster. Consequently, it is not clear whether 
greater numbers of vacuoles were lost or fewer vacuoles were formed in cells with 
decreased cytokeratin-8 expression. Future studies of cytokeratin-8’s involvement 
during embryonic NC fate determination and notochord morphogenesis would provide 
a clearer picture of how cytokeratin-8 might participate in vacuologenesis. 
 To explore how the co-expression of cytokeratin-8 and vimentin IFs, in addition 
to cytosolic vacuoles, are associated with the NC and chordoma cell phenotype, cell 
clustering and gene expression were examined in siKRT8- and siVIM-cells relative to 
siNEG-cells. In the developing notochord and chordomas, cells tend to aggregate in 





more significant role in cell-substrate adhesions compared to cytokeratin IFs, which 
have been more strongly associated with cell-cell adhesions [91], [98], [132, p.].  This 
is consistent with developmental changes in the notochord, as cytokeratin expression 
and the presence of cell clusters are both reduced with maturation. In addition to 
decreased cytokeratin expression, vimentin expression tends to increase with notochord 
development, which has been associated with a decrease in the desmosomal protein 
desmoplakin [157]. In contrast, cytokeratin IFs form direct attachments to desmosomes 
for the formation of cell-cell adhesions. Based on these findings, we decided to examine 
the effect of decreased vimentin and cytokeratin-8 expression on the ability of 
chordoma cells to form cell clusters on soft, BME gels, which have previously been 
shown to promote NC clustering [144]. Knockdown of vimentin and, to our surprise, 
cytokeratin-8 did not appear to affect chordoma cell clustering, suggesting IFs are not 
essential for the formation of chordoma cell-cell adhesions.  
 For gene expression analysis, the expression of T brachyury (T), Sonic 
Hedghog (SHH), and N-cadherin (CDH2) were examined, as these genes are highly 
expressed in NCs and chordoma [42], [40], [43]–[47]. When cells were examined six 
days after transfection with siRNA, we did not find any differences in the expression 
of T, SHH, and CDH2 in siKRT8- and siVIM-cells relative to siNEG-cells. Similar to 
cell clustering results, this suggests the expression of phenotypic genes is not dependent 
on IF protein expression in NCs and chordoma cells. Because siKRT8-cells were found 
to have reduced cytosolic vacuoles, this also suggests the expression of phenotypic 
genes is not dependent on the presence of cytosolic vacuoles.  This is in agreement with 





are essentially decoupled [70]. While immediate effects of cytokeratin-8 and vimentin 
knockdown on gene expression and cell clustering were not observed, long-term stable 




 To our knowledge, this is the first study to reveal the involvement of cytokeratin 
IFs in the vacuolated cytoplasm of chordoma cells. Although additional studies are 
required to elucidate the mechanism, our results suggest cytokeratin-8 IFs are critical 
for the vacuolation of NCs and chordoma cells, and are consistent with the previously 
observed concomitant loss of cytokeratin expression and vacuoles in mature NP cells. 
Insight into factors that function to maintain the NC phenotype is critical for assisting 
in the development of regenerative therapies for disc degeneration and targeted 










Chapter 4: The Roles of Vimentin and Cytokeratin-8 
Intermediate Filaments in Chordoma Cell Mechanobiology 
 
4.1 Introduction 
 Abnormal changes in the mechanical properties of the ECM affect normal cell 
function and are associated with various diseases. For instance, degenerated IVDs have 
been reported to be stiffer than normal discs [158]. Additionally, tumors tend to be 
stiffer than healthy tissue and increased ECM stiffness has been linked to a malignant 
cell phenotype [13], [14]. Cells are able to probe the mechanical properties of their 
surrounding ECM through traction forces and respond by adjusting their focal 
adhesions, cytoskeleton, and mechanical properties. Ultimately, these adjustments can 
affect cell behaviors such as proliferation and migration. Mechanical cues are important 
determinants of cell function and have shown promise as cancer biomarkers, as cell 
deformability and traction forces are found to increase in cancer cells [114]–[118].  
 Cell stiffness, traction force generation, and mechanosensitivity have primarily 
been attributed to F-actin. However, increasing evidence supports roles for 
microtubules and IFs in these processes. NCs, observed in the immature NP and 
chordoma, co-express cytokeratin and vimentin IFs, a unique cellular characteristic that 
is not uncommon in cells of developing tissues and cancer cells [96], [98]. In contrast, 
mature NP cells typically only express vimentin IFs [44]. Cytokeratin IFs are composed 
of heterodimers formed between acidic, type I cytokeratins (9-20) and basic, type II 
cytokeratins (1-8) and are characteristically expressed in epithelial cells. The 





express cytokeratins 8, 18, and 19. For filament formation, cytokertin-8 and -18 
typically dimerize together, while cytokeratin-19 has been suggested to be capable of 
substituting for cytokeratin-18 [131]. Vimentin IFs are composed of vimentin 
monomers and are normally expressed in mesenchymal cells.  
 Individually, vimentin and cytokeratin IFs have been found to be involved in 
various cell mechanical properties and behaviors. Both vimentin and cytokeratin IFs 
interact with actin filaments, and changes in their expression and organization have 
been shown to affect actin stress fibers and cell traction forces [5], [6]. Additionally, 
vimentin and cytokeratin IFs have been found to contribute to cell stiffness. For 
example, vimentin deficient fibroblasts and cytokeratin deficient keratinocytes were 
found to be less stiff than wild type cells [3], [4]. Decreased vimentin and cytokeratin 
expression has also been observed to cause substrate stiffness dependent changes in 
cell spreading [7, p. 18], [8]. In certain cancers, it is suggested that the co-expression 
of vimentin and cytokeratin IFs encourages cell invasion and a metastatic cell 
phenotype [9], [16], [17]. However, the functional roles of vimentin and cytokeratin 
IFs in chordoma cells are unknown.  
 In this study, we investigated the involvement of vimentin and cytokeratin IFs 
in NC mechanical properties and functions. We used RNAi to knock down vimentin 
and cytokeratin-8 expression in a human chordoma cell line (MUG-Chor1) and 
subsequently examined cell stiffness, traction forces, and sensitivity to substrate 
stiffness. Our findings indicate that vimentin IFs are involved in chordoma cell 





expression resulted in decreased cell longitudinal modulus, increased cell traction 
forces, and disrupted cell sensitivity to substrate stiffness.  
 
4.2 Materials and Methods 
4.2.1 Cell Culture 
 MUG-Chor1 chordoma cells (ATCC Cat# CRL-3219, RRID:CVCL_9277) 
were cultured in Iscove's Modified Dulbecco's Medium: Roswell Park Memorial 
Institute 1640 Medium (4:1) (Gibco/Thermo Fisher Scientific) supplemented with 10% 
FBS (Gibco/Thermo Fisher) and 1% Penicillin-Streptomycin (Gibco/Thermo Fisher). 
Complete media exchange was completed every 2-3 days and cells were cultured at 
37°C, 5% CO2. 
 
4.2.2 Transfection of siRNA 
 To knockdown vimentin and cytokeratin-8 expression, chordoma cells were 
transfected with siRNA, as previously described. Cells were plated at a density of 
10,000 cells/cm2 on rat tail type I collagen (Advanced BioMatrix) absorbed (50 μg/ml) 
on TCTP. Twenty-four hours after plating, cells were transfected with Silencer Select 
Pre-designed siRNA (Ambion/Thermo Fisher) targeting either KRT8 (s7970), VIM 
(s14798), or Silencer Select Negative Control No. 1 siRNA (Ambion/Thermo Fisher) 
using Lipofectamine 2000 (Invitrogen/Thermo Fisher) diluted in reduced serum opti-
MEM (Thermo Fisher). Cells were incubated with transfection reagents for 24h. Six 





processed for the analysis of cell spreading, traction forces, contraction of collagen, 
and stiffness. 
 
4.2.3 Polyacrylamide Gel Preparation 
 Polyacrylamide (PA) gels corresponding to stiffnesses of 0.42 kPa (3% 
acrylamide + 0.06% bis acrylamide), 5 kPa (8% acrylamide + 0.07% bis acrylamide), 
and 13 kPa (8% acrylamide + 0.2% bis acrylamide) were prepared on glass coverslips. 
Gel stiffness for these acrylamide to bis-acrylamide ratios have previously been 
confirmed using dynamic mechanical analysis (DMA) and atomic force microscopy 
(AFM) [159], [160]. To enable gel attachment, glass coverslips (25 mm) were first 
coated with 0.1M NaOH, air dried, coated with 3-amino-propyltrimethoxysilane, and 
fixed with 0.5% glutaraldehyde in phosphate buffered saline (PBS). Gel polymerization 
was initiated with 10% ammonium persulfate and catalyzed with N,N,N’,N’-
Tetramethylethylenediamine (TEMED). For traction force microscopy, fluorescence 
beads (1 μm) were added to the gel solution prior to initiating polymerization. Gel 
solutions (30 μl) were added onto activated glass coverslips and distributed evenly 
across the surface by placing an additional coverslip of equivalent size on top of the 
solution. Following 30 minutes of polymerization, the top coverslip was removed and 
gels were treated with sulfo-SANPAH for the chemical crosslinking of either type I 
collagen (Advanced BioMatrix) or laminin (MilliporeSigma, Burlington, MA, USA) 







 Immunofluorescence was used to visualize cytoskeletal proteins and examine 
cell spreading. Cells were fixed with 4% PFA, permeabilized using 0.1% Triton X-100, 
and labelled with rabbit IgG anti-vimentin [SP20] (Thermo Fisher Scientific, Cat# 
MA5-16409 , AB_2537928) or mouse IgG1 anti-cytokeratin-8 [M20] (Abcam, Cat# 
ab9023 RRID:AB_306948) antibodies. A biotinylated (anti-rabbit IgG) secondary 
antibody (Vector Laboratories, Cat# BA-1000, RRID:AB_2313606) was used in 
combination with Texas Red-labelled streptavidin (Vector Laboratories) to visualize 
vimentin. An Alexa Fluor 594-conjugated (anti-mouse IgG) secondary antibody 
(Thermo Fisher Scientific, Cat# A-11032, RRID:AB_2534091) was used to visualize 
cytokeratin-8. Cells were stained with Alexa Fluor 488 Phalloidin (Invitrogen/Thermo 
Fisher Scientific) to visualize F-actin, and DAPI (Invitrogen/Thermo Fisher Scientific) 
was used as a nuclear counterstain. A Nipkow (spinning) disk-equipped Olympus IX81 
microscope was used to capture images at x100 magnification. Confocal fluorescence 
images were taken at x600 magnification and Z-stacks (1 μm slices) were projected 
into a single image for analysis. ImageJ was used to quantify the fluorescence intensity 
of labelled proteins. Cells were manually traced and the corrected total cellular 
fluorescence (CTCF) was calculated per cell using the following equation:  CTCF = 
[integrated density – (area of selected cell x mean fluorescence of background 
reading)]. The corrected mean cellular fluorescence (CMCF) per cell was then 







4.2.5 Cell Spreading 
 Control and siRNA-mediated vimentin and cytokeratin-8 knockdown cells 
were plated at a density of 2,000 cells/cm2 onto PA gels or glass coated with either type 
I collagen or laminin (50-65 μg/ml). After 20h of culture, cells were fixed with 4% PFA 
and immunostained, as described above. Samples were imaged under phase and 
fluorescence microscopy (100x magnification). Cells stained for F-actin were used to 
measure cell area and circularity (shape factor) in ImageJ (https://imagej.nih.gov/ij/,  
RRID:SCR_003070). For each condition, 3 independent experiments were performed 
and 72-75 cells were analyzed. 
 
4.2.6 Traction Force Microscopy 
 Control and vimentin and cytokeratin-8 knockdown cells were plated at a low 
cell density onto 5 kPa PA gels coated with type I collagen (50 μg/ml). To examine the 
contribution of actomyosin-mediated contractility in traction force generation, cells 
were treated with 50 µM (-)-blebbistatin (MilliporeSigma). Following approximately 
20h of culture, cells were imaged under phase and beads under fluorescence 
microscopy (400x magnification). Cells were then detached from the gel surface using 
0.25% trypsin-EDTA (1x) and beads were re-imaged under fluorescence. Fluorescence 
bead images of the same (x,y) position before and after cell detachment were aligned 
using ImageJ to account for shifting of the sample. Bead images were processed with 
MATLAB software generated by the Danuser Lab to calculate bead displacement and 





 In ImageJ, phase images of cells were used to trace the cell boundary and create 
a mask of the cell, where the area under the cell was white and the surrounding area 
black. To extract traction stresses immediately under the cell, an element-by-element 
product of two matrices was calculated using the cell’s mask and the corresponding 
traction map generated by traction force reconstruction. The resulting matrix of traction 
stress values was used to determine the total force, maximum stress, and average stress 
exerted by each cell. The total force exerted by a single cell was calculated as a 
summation of the traction force magnitudes across the cell area. The total force was 
normalized by the cell area and reported as the cell’s average traction stress. A 
maximum stress value, corresponding to the stress at a particular point (pixel within 
captured image), was also determined for each cell.  
 
4.2.7 Collagen Gel Contraction  
 Collagen gels were prepared by mixing 9 parts of 2.5 mg/ml rat tail type I 
collagen (Advanced BioMatrix) with 1-part neutralization solution (Advanced 
Biomatrix). Control and vimentin and cytokeratin-8 knockdown cells suspended in 
chordoma growth media were mixed into collagen pre-gel solutions for final cell and 
collagen concentrations of 1x106 cells/ml and 0.75 mg/ml, respectively. Collagen 
solutions containing cells were added to 48 well plates (250 μl/well) and allowed to 
incubate for 20 minutes at room temperature. Once gels had formed, a scoopula was 
used to detach gels from the edges of the well and each gel was transferred to 5 ml of 
media in a 6 well plate. Gels were cultured at 37C, 5% CO2 for 8 days and imaged daily 





microscope. In ImageJ, captured images were used to measure gel surface areas and 
the percent of the initial gel surface area was calculated for each time point. Four 
independent experiments were performed for each group and data are reported as the 
average ± SEM. 
 
4.2.8 Brillouin Confocal Microscopy 
 The principle of Brillouin scattering is based on the interaction of incident 
photons with collections of molecules oscillating within matter (referred to as phonons) 
resulting in a frequency shift in the gigahertz range. Brillouin frequency shift is related 
to the longitudinal modulus (constrained ratio of axial stress to axial strain) by the 
equation M’ = (ρλ2*Ω2)/(4n2), where M’ is the real part of the longitudinal modulus, ρ 
is the sample mass density, Ω is the frequency shift, λ is the wavelength of incident 
light, n is the index of refraction of the sample. Since the ratio of ρ/n2 varies 
insignificantly in cell samples [162], Ω is positively correlated to M’. Prior research in 
cell samples has established a correlation between the longitudinal modulus, as 
extracted by Brillouin confocal microscopy, and the Young’s modulus, as calculated 
from AFM, thus confirming Brillouin shift as a proxy for mechanical properties within 
a material [163].  
  Brillouin instrumentation used for these experiments was similar to previous 
reports [163], [164]. A single mode linearly-polarized laser with 532 nm or 660 nm 
wavelength was focused into the sample using a 40X/0.6 NA objective. Brillouin 
mapping was performed in the XY plane (parallel to the gel) through the mid-plane of 





siNEG-, siVIM-, and siKRT8-cells were cultured as previously described and plated 
on 5 kPa PA gels coated with type I collagen. A total of 65 siNEG-, 34 siVIM-, and 34 
siKRT8-cells were analyzed in total, measured across 7 experimental days. To extract 
the average Brillouin frequency shift for a cell, values below 6.25 GHz, corresponding 
to extracellular medium, were removed and the remaining cell area was averaged. Both 
circular and attached cells were analyzed, and siVIM and siKRT8 were normalized to 
the average of their respective circular or attached siNEG control group measured on 
the same day.  
 
4.2.9 Statistical Analysis 
 Statistical analyses were completed using SPSS (http://www-
03.ibm.com/software/products/en/spss-statistics/,  RRID:SCR_002865). For all 
studies, Kruskal-Wallis followed by Mann-Whitney U tests for independent samples 
were performed. Statistical significance was set to (𝛼 = 0.05). 
 
4.3 Results 
4.3.1 Knockdown of Vimentin Disrupts Chordoma Cell Mechanosensitivity to Substrate 
Stiffness 
 To examine the involvement of vimentin and cytokeratin-8 IFs in chordoma 
cell mechanosensing of substrate stiffness, knockdown cells were plated on collagen 
(Col-PA) or laminin (Lam-PA) coated PA gels of varied stiffness. Cell area and 
circularity were measured after 20h of culture. On Col-PA gels, vimentin knockdown 





with negative control siRNA (siNEG-cells) and cytokeratin-8 knockdown (siKRT8) 
cells (Figure 4.1a, b). While these differences were observed on Col-PA gels of all 
stiffnesses (0.42, 5, 13 kPa), they were not significant on stiffer (13 kPa) substrates. 
Similarly, on 5 kPa Lam-PA gels, siVIM-cell area was significantly larger relative to 
siNEG-cells (Figure 4.1a). However, on soft (0.42 kPa) Lam-PA gels, all cell types had 
a small and circular morphology (Figure 4.1a, b). All cell types had significantly larger 
cell areas, corresponding to decreased circularity, on stiff (13 kPa) compared to soft 
(0.42 kPa) gels except for siVIM-cells on Col-PA gels (Figure 4.1a, b).  
 On soft (0.42 kPa) gels, cells were significantly larger (increased cell area) and 
less circular on collagen compared to laminin for all cell types (Figure 4.1a, b). With 
increasing PA gel stiffness, the effect of substrate composition on cell area and 
circularity was less apparent. On glass surfaces, siVIM- and siKRT8-cells had 
significantly larger cell areas on laminin than collagen (Figure 4.1c). Although 
differences were not observed between siKRT8- and siNEG-cell areas on PA gels, 








Figure 4.1: The effect of vimentin and cytokeratin-8 knockdown on chordoma cell sensitivity 
to substrate stiffness. (a) Cell area and circularity of cells on PA gels of varying stiffness and 
substrate protein reported as average ± SEM. p < 0.05: * relative to same stiffness same cell 
type on collagen; # relative to same protein same cell type on 5kPa; + relative to same protein 
same cell type on 13kPa; % relative to same stiffness same protein siNEG-cells; & relative to 
same stiffness same protein siKRT8-cells; (b) Representative fluorescence images of chordoma 
cells on soft and stiff PA gels coated with either laminin or type I collagen labeled for F-actin 
(green), and vimentin (red) or cytokeratin-8 (magenta); (c) Cell area and circularity of cells on 
glass reported as average ± SEM. p < 0.05: * relative to same cell type on collagen; % relative 
to same protein siNEG-cells; $ relative to same protein siVIM-cells. 
 
4.3.2 Cell Traction Forces Increase in Chordoma Cells Lacking a Continuous Vimentin 
Network 
 To investigate the role of vimentin and cytokeratin-8 IFs in chordoma cell 





μm fluorescence beads. To minimize effects due to cell size variation of siVIM-cells 
relative to siNEG- and siKRT8-cells observed on 5 kPa Col-PA gels, cells of similar 
size were chosen for analysis (Appendix B; Figure B.2). Additionally, the sum of 
traction force magnitudes across the cell (total traction force), was normalized by cell 
area to calculate the average traction stress for each cell. The maximum traction stress 
exerted by each cell was also calculated to examine localized traction stress. On 
average, siVIM-cells had significantly larger maximum traction stresses when 
compared to siKRT8- and siNEG-cells (Figure 4.2c). A similar trend was observed 
when analyzing the average traction stress, which was increased in siVIM-cells 




Figure 4.2: Traction force analysis of vimentin and cytokeratin-8 knockdown chordoma cells. 





chordoma, siNEG-, siVIM-, and siKRT8-cells on 5 kPa polyacrylamide gels coated with type 
I collagen. Scale bars: 25 µm; (b) Average traction stress and (c) Normalized maximum traction 
stress of siNEG- (N=46), siVIM- (N=43), and siKRT8- (N=44) cells reported as average ± 
SEM. *p < 0.05; ***p < 0.001. 
 
 To examine the involvement of actin in cell traction forces, actin was labelled 
with Alexa Fluor 488 Phalloidin to visualize stress fibers and actin content was semi-
quantitatively determined from fluorescence microscopy. Despite differences in 
traction forces, cells were not found to have visual differences in actin stress fibers 
(Figure 4.3a) or statistically significant differences in fluorescence intensities of actin 
staining (Figure 4.3b). To further investigate the mechanism responsible for increased 
traction forces of siVIM-cells, cells were treated with 50 µM (-)-blebbistatin to inhibit 
myosin II and prevent actomyosin-mediated contractility. Traction forces exerted by 
blebbistatin-treated siVIM-cells were similar to those exerted by siNEG-cells, both of 
which were significantly reduced compared to DMSO-treated control cells (Figure 
4.3c). Following blebbistatin treatment, the average total traction force exerted by 







Figure 4.3: F-actin in knockdown cells and its role in cell traction forces. (a) Representative 
fluorescence images of siNEG-, siVIM, and siKRT8-cells on 5 kPa polyacrylamide gels labeled 
for vimentin (red) or cytokeratin-8 (magenta), and F-actin (green). Scale bars: 15 µm; (b) 
Corrected mean cell fluorescence of F-actin in siNEG- (N=38), siVIM- (N=21), and siKRT8-
(N=27) cells reported as average ± SEM; (c) Representative phase images and corresponding 
traction maps of siNEG- and siVIM-cells treated with 50 µM (-)-blebbistatin or DMSO on 5 






4.3.3 Vimentin and Cytokeratin-8 Intermediate Filaments Are Not Essential for 
Contraction of Collagen Gels 
 To gain a better understanding of the functional consequences of altered traction 
force, we examined the effects of decreased vimentin and cytokeratin-8 expression on 
the ability of chordoma cells to contract collagen gels. Type I collagen gels (0.75 
mg/ml) containing siNEG-, siVIM-, and siKRT8-cells all became significantly smaller, 
as measured by gel surface area, compared with no-cell control gels at all time points 
(Figure 4.4). While siVIM-cells exhibited increased traction forces relative to siNEG-
cells in 2D culture, decreased vimentin expression did not appear to alter contraction 
of collagen gels (Figure 4.4). Surprisingly, we found that siKRT8-cells consistently 
contracted collagen gels less than siVIM- and siNEG-cells after 1 day of culture (Figure 
4.4), but exhibited faster contraction thereafter, such that there was no difference in gel 
size by day 8. 
 
 
Figure 4.4: The involvement of vimentin and cytokeratin-8 in chordoma cell contraction of 
collagen in a 3D culture system. (a) Bright field images of collagen gels embedded with siNEG-





Scale bar: 0.5 mm; (b) Change in gel surface area over 8 days calculated as a percent of the 
original gel surface area reported as daily averages ± SEM. 
 
 
4.3.4 Vimentin Intermediate Filaments Contribute to Chordoma Cell Stiffness 
 The contribution of vimentin and cytokeratin IFs to chordoma cell longitudinal 
modulus was investigated using vimentin (siVIM) and cytokeratin-8 (siKRT8) 
knockdown cells. Following overnight culture on 5 kPa Col-PA gels, cell longitudinal 
modulus was measured using Brillouin confocal microscopy. To control for cell size, 
cells of similar spread area were selected for analysis. As a result, the average cell area 
and circularity were not statistically different comparing siNEG, siVIM, and siKRT8 
cells measured for cell stiffness analysis (Appendix B; Figure B.1). Cell modulus was 
significantly decreased in siVIM-cells relative to siNEG- and siKRT8-cells (Figure 
4.5b). In contrast, the modulus of siKRT8-cells was not significantly different (p= 1.0) 
than the modulus of siNEG-cells (Figure 4.5b).  
 
 
Figure 4.5: The effect of vimentin and cytokeratin-8 knockdown on cell longitudinal modulus. 





cells. Brillouin shift, represented by the color bar, scales from 6.1 GHz to 6.3 GHz, with 
increased values referring to increased Brillouin shift (and longitudinal modulus). Scale bars: 
50 µm; (b) Brillouin shift of siVIM- and siKRT8-cells normalized to siNEG-cells. Data of each 
siVIM and siKRT8 cell is reported. *p < 0.0001: significance between siVIM- and siNEG-
cells, as well as siVIM- and siKRT8-cells. 
 
4.4 Discussion 
 Because IF protein expression is typically tissue-specific, it is believed that 
vimentin and cytokeratins have specialized roles. While cell mechanics is primarily 
attributed to F-actin, both vimentin and cytokeratin IFs have been found to contribute 
to cell mechanical properties such as cell stiffness and play functional roles in cell 
mechanosensitivity and contractility [3]–[8]. Additionally, the co-expression of 
vimentin and cytokeratin IFs has been suggested to enhance cancer cell migration and 
invasion. However, the roles of vimentin and cytokeratin IFs in chordoma cells have 
not yet been reported. Results of this study reveal that vimentin IFs are involved in 
chordoma cell mechanobiology. We found that decreased vimentin expression via 
RNAi disrupted chordoma cell mechanosensitivity to substrate rigidity, increased cell 
traction forces, and decreased cell stiffness. Surprisingly, significant differences were 
not observed in chordoma cells with decreased cytokeratin-8 expression. Together, our 
findings suggest that chordoma cell mechanobiology is more dependent on vimentin 
than cytokeratin IFs. 
 The involvement of vimentin and cytokeratin IFs in chordoma cell 
mechanosensitivity to substrate stiffness was examined by measuring cell spread area 
and circularity of vimentin and cytokeratin-8 knockdown chordoma cells cultured on 





cell spreading [165]. This behavior was observed for siNEG chordoma cells and did 
not appear to be affected by decreased cytokeratin-8 expression. In contrast, 
knockdown of vimentin expression appeared to dysregulate chordoma cell 
mechanosensing. Interestingly, significant cell spreading was observed in vimentin 
knockdown cells on 0.42 kPa Col-PA gels, a modulus on the order of brain tissue. This 
contradicts previously reported studies by others showing vimentin knockdown 
reduced cell spreading and adhesions [166], [167]. 
 Visualizing the cytoskeleton via immunofluorescence, we have generally 
observed vimentin IFs to concentrate at the chordoma cell periphery and focal 
adhesions. Similarly, residual vimentin in our vimentin knockdown cells tended to 
localize only at the cell periphery and the distal ends of cell protrusions. However, 
whereas normal chordoma cells also exhibit a vimentin network across the cell body, 
this was completely absent in vimentin knockdown cells. Previous studies have also 
reported the association between vimentin IFs and focal adhesions [81], [91], [133]. 
Additionally, when vimentin was transfected into human breast cancer cells, vimentin 
quickly (within 12 h) became associated with focal adhesions, when the majority of 
vimentin was still in the form of particles and short filaments [91]. It is possible that 
despite decreased vimentin expression, the strong association of residual vimentin with 
focal adhesions is contributing to cell spreading.  
 In addition to significant cell spreading, vimentin knockdown cells cultured on 
5 kPa PA gels exerted greater traction forces than control and cytokeratin-8 knockdown 
cells. Specifically, the maximum traction stress was significantly greater in vimentin 





under the cell, measurements were not skewed by cell area. In support of our findings, 
vimentin depletion in human osteosarcoma cells was found to induce the assembly of 
actin stress fibers and increase cell traction forces [6]. Blebbistatin-treatment of our 
vimentin knockdown cells resulted in decreased traction forces similar to those of 
blebbistatin-treated control cells. Our interpretation of these results is that greater 
traction forces are most likely due to over compensation of F-actin following the loss 
of a vimentin IF network. Others have observed in vimentin knockout cells with 
increased stress fiber assembly, that reintroducing nonfilamentous ‘unit length form’ 
vimentin could not rescue the stress fiber phenotype. However, introduction of full-
length GFP-vimentin was capable of diminishing stress fiber assembly [6]. Despite 
vimentin remnants in our vimentin knockdown cells, the lack of a vimentin IF network 
throughout the cell body may be encouraging the assembly of actin stress fibers, 
leading to increased cell contractility. 
 To further examine the functional impact of vimentin and cytokeratin 
knockdown on cell contractility, we embedded cells within type I collagen gels and 
measured their ability to contract the 3D collagen matrix. Inconsistent with traction 
force observations in 2D, knockdown of vimentin expression did not appear to increase 
cell contractility in 3D culture. However, altered cell traction forces may have a greater 
impact on cell migration, rather than collagen contraction. Examining collagen gels 
over an 8-day period, we found both vimentin- and cytokeratin-deficient cells were 
capable of contracting collagen gels and no significant differences in collagen gel 
diameter were observed when compared to control cells. In contrast with our findings, 





impaired contraction of collagen gels [85]. We may not be observing impaired 
contraction of collagen gels in vimentin knockdown chordoma cells because of their 
continued expression of cytokeratin IFs, which are not present in fibroblasts. When 
compared to fibroblasts, keratinocytes, which co-express cytokeratins and vimentin 
[90], [168], have been found to produce greater collagen gel contraction [169]. The 
decrease in collagen gel contraction we observed in our cytokeratin-8 knockdown cells 
suggests cytokeratin, rather than vimentin, IFs may play a greater role in chordoma cell 
contractility in 3D.  
 Finally, we utilized Brillouin microscopy to measure cell mechanical 
properties. We found cell longitudinal modulus was significantly reduced in vimentin-
knockdown chordoma cells, but unchanged in cytokeratin-8-knockdown cells. Using 
the relationship between Brillouin shift and longitudinal modulus previously reported 
[163], we were able to estimate the percent difference in the Young’s moduli between 
knockdown and control cells. Based on the average Brillouin shift for each sample, we 
estimate the respective Young’s moduli of vimentin- and cytokeratin-8-knockdown 
cells to be approximately 13% and 1% less than that of control cells. Similarly, 
vimentin-deficient fibroblasts have been found to have reduced cell stiffness compared 
to wild-type cells [4], [85], [170], and a comparable decrease (20%) in the Young’s 
modulus of vimentin-null relative to normal fibroblasts has been measured by AFM 
[8]. We may not have observed as great of a decrease in the Young’s modulus as 20% 
because vimentin is not completely ablated in our system. Additionally, our vimentin-
knockdown chordoma cells continue to express cytokeratin IFs, which are not present 





previously found to be 60% more deformable than wild-type keratinocytes which also 
inherently co-express vimentin and cytokeratins [3]. It is unclear whether our 
observations differ for cytokeratin-8-knockdown cells because of the differences in cell 
type, degree of knockdown, or method of measuring cell stiffness. Our findings 




 To our knowledge, this is the first study to investigate the roles of vimentin and 
cytokeratin IFs in chordoma cell mechanobiology. Our findings suggest vimentin IFs 
play a critical role in maintaining cell stiffness, sensing substrate rigidity, and 
generating traction forces in chordoma cells. Because we did not observe significant 
changes in chordoma cell mechanics following cytokeratin-8 knockdown, it is 
suggested vimentin IFs have a more prominent role than cytokeratin IFs.  Mechanical 
cues are critical determinants of cell function and abnormal changes in cell and tissue 
mechanics can lead to disease. Understanding the involvement of vimentin and 
cytokeratin IFs in chordoma cell mechanobiology may provide insight into chordoma 





Chapter 5: The Involvement of Vimentin and Cytokeratin-8 




Chordoma, a malignant tumor that develops from notochordal remnants, is 
often associated with poor prognosis due to delayed diagnosis (1.5 years on average) 
[171], with a propensity toward recurrence (68%) [172], [173], and with resistance to 
radiation [174] and traditional cytotoxic chemotherapeutic agents [1], [66]. Based on 
the sparse clinical data collected on chordoma, the incidence of chordoma metastases 
has been reported to be between 3 to 48% [173], [175].  Similar to other cancers, 
chordoma metastasis increases the risk of tumor-related death [176]. Compared to 
healthy tissue, tumors tend to be stiffer and the increased tissue stiffness has been found 
to promote a malignant cell phenotype [13], [14]. Through integrins and the 
cytoskeleton, cells are capable of probing the mechanical properties of their 
surrounding ECM and adjusting their mechanical properties and behaviors in response. 
As a result, cellular processes, such as migration and proliferation, are affected by cell-
ECM interactions [177], [178]. Cell mechanobiology and ECM rigidity has also been 
associated with cancer cell chemoresistance [179]–[181]. Because we previously found 
decreased vimentin expression affected chordoma cell mechanobiology, we sought to 
further explore the effects on cellular processes associated with cancer progression. 
Cancer cells, including chordoma, commonly co-express vimentin and 
cytokeratin IFs. This co-expression has been hypothesized to promote cell invasion and 





typically enhances cell motility and promotes cancer metastasis. For instance, the 
overexpression of vimentin has been connected to tumor metastasis in a variety of 
cancers such as melanoma [15], prostate carcinoma [19], breast cancer [17], and 
hepatocellular carcinoma [18]. Similarly, decreased vimentin expression has been 
found to reduce cell migration and invasion in cancerous and non-cancerous cells alike 
[10], [12], [85], [103]. Due primarily to its association with increased metastasis, 
vimentin expression is associated with poor cancer prognosis [104]. The role of 
cytokeratin expression in cell migration is less clear than that of vimentin and appears 
to be cancer type-specific. Knockdown of cytokeratins 8 or 18 decreased cell migration 
and invasion in non-small lung cancer and oral squamous cell carcinoma [9], [84], but 
increased cell migration and invasion in liver hepatocellular carcinoma cells [11]. 
Additionally, the overexpression of cytokeratins 8 and 18 have been associated with 
increased migration in melanoma cells [16], but reduced cell invasion in breast cancer 
cells [102].  
IFs have also been suggested to play a role in cancer cell resistance to traditional 
cytotoxic chemotherapeutic drugs, such as cisplatin and paclitaxel. Cisplatin induces 
apoptosis through its direct binding to DNA, and paclitaxel inhibits cell division 
through its specific binding to microtubules. In non-small cell lung cancer and gastric 
cancer cells, EMT suppression, characterized by decreased vimentin expression, was 
found to increase cell sensitivity to cisplatin [20], [22]. Cisplatin sensitivity was also 
increased in epithelial cancer and nasopharyngeal carcinoma cells following the 
knockdown of cytokeratins 8 and 18 [11], [21]. Similarly, knockdown of cytokeratin 





However, decreased expression of cytokeratins 8 and 18 have also been associated with 
poor prognosis in breast and colorectal cancer [108], [109]. While increased expression 
of both vimentin and cytokeratin-8 have been found to contribute to cancer cell 
resistance to chemotherapy, their roles in chordoma chemoresistance have not yet been 
reported.  
Chordoma progression is commonly associated with the expression of various 
genes, including brachyury (T), SHH, and N-cadherin, that are consistently identified 
in chordomas. Both SHH and brachyury play essential roles in embryonic development, 
regulating notochord formation and patterning of the axial skeleton and neural tube. 
However, following embryonic development, overexpression of SHH and brachyury 
have been associated with tumor formation and progression [124], [125]. It is theorized 
that the reactivation of SHH in notochordal remnants could cause a malignant 
transformation [182]. Because of the high, consistent expression of brachyury in 
chordoma tumors, and its significant contribution to chordoma pathogenesis, brachyury 
has been identified as a diagnostic marker and is actively being researched in clinical 
trials as a therapeutic target for chordoma [52], [55], [69], [183]. Increased expression 
of brachyury, SHH, and N-cadherin have all been connected to EMT [125]–[130], 
increased vimentin expression, and enhanced chordoma cell proliferation, migration, 
and invasion [184]. 
In this study, we examined the involvement of vimentin and cytokeratin-8 
expression in chordoma cell migration, invasion, gene expression, and 
chemoresistance. Similar to our previous studies, we accomplished this using RNAi to 





(MUG-Chor1). Our findings suggest that both vimentin and cytokeratin-8 IFs 
contribute to chordoma cell migration, but only vimentin, and not cytokeratin-8, IFs 
are essential for chordoma cell invasion. Further, we found vimentin knockdown 
resulted in decreased SHH expression in chordoma cells cultured on rigid substrates. 
Our data also suggests increased vimentin expression may contribute to chordoma 
chemoresistance. 
 
5.2 Materials and Methods 
5.2.1 Cell Culture 
 Similar to previous studies, MUG-Chor1 chordoma cells (ATCC Cat# CRL-
3219, RRID:CVCL_9277) were cultured in Iscove's Modified Dulbecco's Medium: 
Roswell Park Memorial Institute 1640 Medium (4:1) (Gibco/Thermo Fisher Scientific) 
supplemented with 10% FBS (Gibco/Thermo Fisher) and 1% Penicillin-Streptomycin 
(Gibco/Thermo Fisher). Media was exchanged every 2-3 days and cells were cultured 
at 37°C, 5% CO2. 
 
5.2.2 Transfection of siRNA 
 To decrease vimentin and cytokeratin-8 expression, chordoma cells were 
transfected with siRNA, as previously described. Cells were plated at a density of 
10,000 cells/cm2 onto TCTP coated with rat tail type I collagen (Advanced BioMatrix). 
The following day, cells were transfected with Silencer Select Pre-designed siRNA 
(Ambion/Thermo Fisher) targeting KRT8 (s7970), VIM (s14798), or Silencer Select 





(Invitrogen/Thermo Fisher) diluted in reduced serum opti-MEM (Thermo Fisher) for a 
duration of 24h. Six days after transfection, cells were detached using 0.25% trypsin-
EDTA (1x) and processed for the analysis of cell migration, transwell invasion, and 
viability. Fourteen days after transfection, cells were processed for the analysis of gene 
expression and viability. 
 
5.2.3 Cell Migration 
 Control and vimentin and cytokeratin-8 knockdown cells were plated on bare, 
type I collagen-, or laminin-coated plastic (50-65 μg/ml) in 2 well silicone inserts 
(Ibidi). Cells were suspended in chordoma growth media at a concentration of 1x106 
cells/ml and 70 μl of the cell suspension was added per well of the insert. Following 
24h of culture, culture inserts were removed, leaving a 500 μm cell-free gap between 
two confluent cell monolayers. For each sample, two (x,y) positions of the cell-free gap 
were randomly selected and imaged every 24h for 4 days under phase microscopy 
(100x magnification) using a Nipkow (spinning) disk-equipped Olympus IX81 
microscope. In ImageJ, captured images were used to measure the area of the cell-free 
gap at each time point. For both (x,y) positions, the area of the cell-free gap was divided 
by its length to calculate the average gap width of each sample. For each time point, 
the average gap width was subtracted from the initial gap width to determine the total 
migration distance (μm). Instead of assuming inserts formed cell-free gaps of 500 μm 
in width, the average width of the initial cell-free gap was also calculated. The total 
migration distance for each time point was normalized by the initial gap width and an 





experiments were performed for each group and data are reported as the average ± 
SEM. 
 
5.2.4 Cell Invasion 
 Corning BioCoat Angiogenesis Systems (Corning, Corning, NY, USA) were 
utilized for the analysis of cell invasion. These systems consist of a Corning Fluoroblok 
24-multiwell insert plate with 3 µm pore size Polyethylene Terephtalate (PET) 
membranes that were pre-coated with Corning Matrigel® Matrix. The uniform 
Matrigel coating occludes the PET membrane pores and blocks non-invasive cells. 
Control and knockdown cells were re-suspended in serum-free growth media (2.0 x 105 
cells/ml) and added to the top chamber of the plates onto the Matrigel-coated inserts 
(50,000 cells/insert). Growth media containing 10% FBS was then added as a 
chemoattractant through a sample port to the bottom chamber of the plate. Cells were 
incubated for 48 hours at 37°C, 5% CO2. After 24 hours, an additional 250 µl/insert of 
serum-free media was added to the top chambers to ensure complete hydration over the 
48-hour incubation period.  
 To visualize live, invaded cells at the 48-hour time-point, inserts were stained 
with calcein AM (Invitrogen/Thermo Fisher) and the nuclear counterstain Hoechst 
33342 (Invitrogen/Thermo Fisher Scientific). Because the Corning Fluoroblok 
membrane is designed to block the passage of light from 490-700 nm, we were able to 
specifically detect the fluorescence of cells that had passed through the membrane 
using a Nikon Ti2-E Inverted Automated Microscope. Fluorescence images were 





scan and images were subsequently stitched together to visualize all of the invaded 
cells/insert. Calcein AM-stained cells were counted using NIS-Elements Software and 
the total number of invaded cells/insert was quantified. Four separate samples were 
examined for each cell type and data are reported as the average ± SEM.  
 
5.2.5 Collagen Gel Preparation 
 Six days after transfection, cells were detached using 0.25% trypsin-EDTA (1x) 
and seeded on top of or embedded within type I collagen gels for an additional 8 days 
of culture. Collagen pre-gel solutions were prepared by mixing 9 parts of 4 mg/ml rat 
tail type I collagen (Advanced BioMatrix) with 1-part neutralization solution 
(Advanced Biomatrix). For 2D culture, pre-gel solutions (1 ml) were added to 6-well 
tissue culture-treated plates and incubated for 1 hour at 37°C to promote gelation. The 
final gel thickness was estimated to be approximately 1 mm. Cells were plated on top 
of gels at a density of 10,000 cells/cm2. For 3D culture, cells suspended in chordoma 
growth media were mixed into collagen pre-gel solutions for final cell and collagen 
concentrations of 1x106 cells/ml and 2.7 mg/ml, respectively. Collagen solutions 
containing cells were added to 48 well plates (125 μl/well) and allowed to incubate for 
20 minutes at 37°C. Once gels had formed, 500 µl of chordoma growth media was 
added on top of each gel. After 8 days of culture, corresponding to 14 days post-






5.2.6 Gene Expression 
 As previously described, RNA isolation was performed using phenol-
chloroform extraction. Cells were lysed with TRIzol (Ambion/Thermo Fisher 
Scientific) and RNA was precipitated from the resulting lysate using chloroform and 
isopropanol. To quantify expression of VIM, KRT8, T, SHH, CDH2, and 18S (Table 
3.1), reverse transcribed RNA samples underwent qRT-PCR (MyiQ System, BioRad) 
using SsoFast EvaGreen Supermix (BioRad, Hercules, CA, USA). Using 18S as a 
housekeeping gene, relative quantitation of qRT-PCR data was performed using the 
ΔΔCt method. Briefly, ΔCt values were computed by subtracting Ct values of the 18S 
control gene from those of each gene of interest (i.e., ∆𝐶𝑡 𝑆𝐻𝐻 =  𝐶𝑡 𝑆𝐻𝐻 − 𝐶𝑡 18𝑆). For 
each gene of interest, ΔΔCt values were computed by subtracting ΔCt values of the 
reference sample (e.g. cells transfected with negative control siRNA), from ΔCt values 
of cells transfected with siRNA targeting either VIM or KRT8 (∆∆𝐶𝑡 𝑆𝐻𝐻;𝑉𝐼𝑀 𝑠𝑖𝑅𝑁𝐴 =
 ∆𝐶𝑡 𝑆𝐻𝐻;𝑉𝐼𝑀 𝑠𝑖𝑅𝑁𝐴 − ∆𝐶𝑡 𝑆𝐻𝐻;𝑁𝐶 𝑠𝑖𝑅𝑁𝐴). Using ΔΔCt values, relative changes in mRNA 
levels (fold difference) were expressed through the exponential relation: 2-ΔΔCt. 
Technical replicates for each sample, along with appropriate no RT and no template 
controls, were performed in triplicate. Data collected over three independent cell 
transfections (n=3) for each of the siRNA groups are reported as the average of the 
range of the fold difference, which incorporates the standard deviation of the ΔΔCt 






5.2.7 Western Blotting 
 For protein extraction, cells were detached from culture surfaces using 0.25% 
trypsin-EDTA (Gibco/Thermo Fisher) and re-suspended in a lysis buffer supplemented 
with a 1:100 concentration of protease inhibitor cocktail (Thermo Fisher), as previously 
described. Protein concentrations were determined using a modified Lowry assay with 
a Folin-Phenol color reaction detected by a ND-1000 Spectrophotometer. For SDS-
Page, protein extracts were mixed (1:1) with a loading buffer (13% (v/v) Tris-HCl, 
20% (v/v) glycerol, 4.6% (w/v) SDS, 0.02% (w/v) bromophenol blue, 200 mM 
dithiothreitol) and subsequently loaded (8µg of protein per sample) into pre-cast 
Criterion Tris-HCl gels (BioRad). Proteins were electrophoretically transferred to 
polyvinylidene fluoride membranes and detected using rabbit IgG anti-vimentin 
polyclonal (Abcam) and mouse IgG1 anti-cytokeratin-8 [M20] (Abcam) antibodies in 
combination with Vectastain ABC-AmP for chromogenic detection. GAPDH, detected 
with a rabbit IgG anti-GAPDH [EPR16884] (Abcam) antibody, was used as a loading 
control. Semi-quantitative analysis was performed using ImageJ 
(https://imagej.nih.gov/ij/,  RRID:SCR_003070) to determine vimentin and 
cytokeratin-8 band intensities normalized to GAPDH.  Protein expression levels are 




 Immunofluorescence was used to verify IF knockdown and visualize 





As previously described, cells were fixed with 4% PFA, permeabilized using 0.1% 
Triton X-100, and labelled with rabbit IgG anti-vimentin [SP20] (Thermo Fisher 
Scientific) or mouse IgG1 anti-cytokeratin-8 [M20] (Abcam) antibodies. A biotinylated 
(anti-rabbit IgG) secondary antibody (Vector Laboratories) was used in combination 
with Texas Red-labelled streptavidin (Vector Laboratories) to visualize vimentin. An 
Alexa Fluor 594-conjugated (anti-mouse IgG) secondary antibody (Thermo Fisher 
Scientific) was used to visualize cytokeratin-8. Cells were stained with Alexa Fluor 
488 Phalloidin (Invitrogen/Thermo Fisher Scientific) to visualize F-actin, and DAPI 
(Invitrogen/Thermo Fisher Scientific) was used as a nuclear counterstain. A Nipkow 
(spinning) disk-equipped Olympus IX81 microscope was used to capture images at 
x100 magnification. Confocal fluorescence images were taken at x600 magnification 
and Z-stacks (1 μm slices) were projected into a single image for analysis. 
 
5.2.9 Polyacrylamide Gel Preparation 
 PA gels corresponding to stiffnesses of 1 kPa (3% acrylamide + 0.2% bis 
acrylamide) and 13 kPa (8% acrylamide + 0.2% bis acrylamide) were prepared on glass 
coverslips (12-15mm). The stiffness of gels formed with these acrylamide to bis-
acrylamide ratios has previously been confirmed using DMA and AFM [159], [160]. 
As previously described, glass coverslips were coated with 0.1M NaOH, air dried, 
coated with 3-amino-propyltrimethoxysilane, and fixed with 0.5% glutaraldehyde in 
PBS. Pre-gel solutions were added onto activated glass coverslips and distributed 
evenly across the surface by placing a coverslip of equivalent size on top of the solution. 





TEMED. After 30 minutes, the top coverslip was removed and polymerized gels were 
treated with sulfo-SANPAH for the chemical crosslinking of laminin (MilliporeSigma) 
to the gel surface. 
 
5.2.10 Chemotherapy Drug Sensitivity  
 The effects of IF protein knockdown and substrate stiffness on the sensitivity 
of chordoma cells to standard chemotherapeutic agents were examined in vitro using 
an alamarBlue® cell viability assay (Thermo Fisher Scientific). Thirteen days after 
transfection, vimentin knockdown cells were transferred to 24- or 48-well tissue 
culture-treated plates. For substrate stiffness analysis, non-transfected chordoma cells 
were plated on BME gels, laminin-coated PA gels (1, 13kPa), and laminin-coated glass. 
Laminin-rich BME gels were formed by dispensing unpolymerized BME (Trevigen) 
onto 12-15 mm diameter glass coverslips (~60 µl/cm2) and incubating for 30 minutes 
at 37C. Laminin-coated glass substrates were prepared by absorbing laminin (65 µg/ml) 
from EHS murine sarcoma basement membrane (MilliporeSigma) onto glass 
coverslips (12-15mm). Cells were cultured overnight to promote cell attachment before 
treatment with 20 µM cisplatin (Selleck Chemicals, Houston, TX, USA) or 5 µM 
paclitaxel (Selleck Chemicals). Due to the interference of serum with the alamarBlue 
cell viability reagent, drugs were diluted in reduced-serum media (2% FBS). Untreated 
or DMSO-treated reduced-serum media was added to cells to serve as controls for 
cisplatin and paclitaxel, respectively. After two or five days of treatment, the 
alamarBlue cell viability reagent was added to cells. Following 24h incubation with 





drugs, plates were analyzed using a SpectraMax® M5 Microplate Reader (Molecular 
Devices, San Jose, CA, USA). Increased incubation time with alamarBlue allowed for 
the detection of small differences in cell viability. Relative fluorescence unit (RFU) 
values of samples containing the same media, but no cells, were subtracted from cell 
samples to calculate corrected RFU values. The percent cell survival was determined 
using the following equation: [(corrected average RFU of treated cells / corrected 
average RFU of untreated cells) x 100]. Data are reported as the average ± SEM. 
 
5.2.11 Statistical Analysis  
 Statistical analyses were completed using SPSS (http://www-
03.ibm.com/software/products/en/spss-statistics/, RRID:SCR_002865) and statistical 
significance was set to (𝛼 = 0.05). One-sample t-tests were used to compare the 
relative expression of cytokeratin-8 and vimentin, as measured by Western blot, in 
siVIM- and siKRT8-cells to that of siNEG-cells. One-sample t-tests were also used to 
compare the percent cell survival of cells treated with cytotoxic drugs to the percent 
cell survival of untreated cells (100%). Two-sample t-tests were used to compare gene 
expression of siVIM- and siKRT8-cells to siNEG-cells. For all other studies, Kruskal-
Wallis followed by Mann-Whitney U tests for independent samples were performed. 
 
5.3 Results 
5.3.1 Knockdown of Vimentin and Cytokeratin-8 Decreases Chordoma Cell Migration 
 Modified wound healing assays, utilizing 2 well inserts with a defined cell-free 





in chordoma cell migration. Because chordoma cells were found to migrate at a slow 
rate, cell-free gaps were examined over 96h. On bare and collagen-coated plastic, 
siVIM and siKRT8 cell migration was decreased compared to siNEG-cells (Figure 
5.1a, b). Significant differences were observed at 48, 72, and 96h on bare plastic and at 
48h on collagen (Figure 5.1a, b). Differences in migration were not observed between 
cell types on laminin-coated plastic (Figure 5.1c). Compared to other substrates, cell 







Figure 5.1: The effect of vimentin and cytokeratin-8 knockdown on chordoma cell migration 
in 2D. (a), (b), and (c) Representative phase images of siNEG-, siVIM-, and siKRT8-cells on 
bare, type I collagen-, and laminin-coated plastic at 0 and 72 hours after removing cell divider. 
Scale bars: 100 µm. Cell migration normalized to cell-free gap at 0h reported as the daily 
average ± SEM. p < 0.05: * relative to siVIM- and siKRT8-cells; $ relative to siKRT8-cells. 
 
5.3.2 Chordoma Cell Invasion is Dependent on Vimentin Intermediate Filaments 
 The invasive behavior of chordoma cells with vimentin and cytokeratin-8 RNAi 





Matrigel® Matrix pre-coated PET membranes (3 µm pores). Similar to cell migration 
in 2D culture, significantly fewer siVIM-cells invaded through the Matrigel membrane 
compared to siNEG-cells (Figure 5.2a, b, d). In contrast, the number of invaded 
siKRT8-cells was not statistically different from the number of invaded siNEG-cells 
(Figure 5.2a, c, d).  While markedly more siKRT8-cells invaded compared to siVIM-
cells, these differences were not statistically different (Figure 5.2b, c, d). 
 
 
Figure 5.2: The effect of vimentin and cytokeratin-8 knockdown on chordoma cell invasion. 





with calcein-AM that have invaded through 3 µm pore-PET membranes coated with Matrigel. 
Scale bars: 500 µm; (d) The number of invaded siNEG-, siVIM-, and siKRT8-cells per insert 
after 48h of culture reported as the average ± SEM. *p < 0.05. 
 
5.3.3 Vimentin Knockdown via RNAi is Stable in Chordoma Cells over Fourteen Days 
of Culture 
 To mitigate cellular side effects from the transfection process, such as decreased 
cell proliferation, and to allow for potential changes in the cell phenotype following IF 
protein knockdown, we chose to increase the culture time of siRNA-transfected cells 
prior to processing. Similar to analyses on day six (Chapter 3.3.3), when cells were 
examined fourteen days after transfection, chordoma cells transfected with siRNA 
targeting VIM (siVIM) exhibited significant decreases in vimentin expression. In 
contrast, cytokeratin-8 expression was not significantly different in siKRT8-transfected 
cells relative to siNEG-transfected cells examined fourteen days after transfection 
(Figure 5.3a). Through semi-quantitative analysis of western blotting, an approximate 
50% decrease in vimentin expression was measured in siVIM-transfected cells 
compared to siNEG-transfected cells (Figure 5.3a). Decreased vimentin expression was 







Figure 5.3: Characterization of cytokeratin-8 and vimentin knockdown in chordoma cells 
fourteen days after transfection with siRNA. (a) Western blot of siKRT8- and siVIM-
transfected cells analyzed relative to siNEG-transfected cells. Data is reported as the average 





GAPDH; (b) Representative bright field and fluorescence images of siNEG-, siKRT8- and 
siVIM-transfected cells. Cytokeratin-8 (red) and vimentin (green). Scale bars: 50 µm. 
 
5.3.4 Knockdown of Vimentin Decreases Sonic Hedgehog Expression in Chordoma 
Cells on Rigid Substrates 
 The expression of phenotypic genes, previously examined six days after siRNA 
transfection (Chapter 3.3.5), was re-examined fourteen days after siRNA transfection. 
Gene expression was examined of cells in 2D (on type I collagen-coated plastic and 
type I collagen gels) and 3D (embedded in type I collagen gels) culture. Both 
knockdown and control cells were cultured on the same substrate for comparison. On 
type I collagen-coated plastic, SHH expression was significantly decreased in siVIM-
cells relative to siNEG-cells (Figure 5.4a). This effect was dependent on culture 
condition, as SHH expression was not decreased in siVIM-cells relative to siNEG-cells 
when cells were cultured on top of or embedded within type I collagen gels (Figure 
5.4b, c). Cytokeratin-8 expression returned to levels comparable to siNEG control at 
fourteen days, indicating knockdown was transient. Not surprisingly, chordoma cell 






Figure 5.4: The effect of vimentin knockdown in chordoma cells on their expression of 
phenotypic genes. Gene expression of cells processed for analysis fourteen days after 
transfection with siRNA. siKRT8- and siVIM-transfected cells analyzed relative to siNEG-
transfected cells cultured (a) in 2D on plastic coated with type I collagen; (b) in 2D on type I 
collagen gels; (c) in 3D in type I collagen gels. *p< 0.05 and **p<0.01, relative to siNEG-cells. 
 
5.3.5 Vimentin Expression May Contribute to Chordoma Cell Resistance to 
Chemotherapeutic Agents 
 To improve our understanding of the relationship between IFs and the response 
of chordoma cells to cytotoxic chemotherapeutic agents, we examined the intensity and 
organization of vimentin and cytokeratin-8 IFs in chordoma cells treated with cisplatin 
via immunostaining and fluorescence imaging. We observed increased fluorescence 
intensity of vimentin in cisplatin-treated chordoma cells compared to untreated 





fluorescence intensity of cytokeratin-8, but appeared to induce changes in cytokeratin-
8 IF organization. In cisplatin-treated cells, cytokeratin-8 was commonly observed to 
be concentrated at the cell nucleus (Figure 5.5). 
 
 
Figure 5.5: The effect of cisplatin treatment on vimentin and cytokeratin-8 intermediate 
filament networks. (a) Representative fluorescence images of cisplatin-treated chordoma cells 
labeled for F-actin (green), vimentin (red), and cytokeratin-8 (magenta). Scale bars: 15 µm. 
 
 To determine the potential involvement of IF integrity in chordoma cell 
chemoresistance to traditional cytotoxic chemotherapy drugs, we analyzed the viability 
of day fourteen vimentin knockdown cells treated with cisplatin. As a positive control, 
we included a parallel group of vimentin knockdown cells treated with paclitaxel, 
which induces cytotoxicity through cytoskeletal disruption, to serve as a gold standard. 
We did not include siKRT8-cells because knockdown was not sustained through 14 
days. Following three days of treatment with both cisplatin and paclitaxel, the average 
percent cell survival of siNEG-cells tended to be greater (~7%) than that of siVIM-





trends were found when the duration of cisplatin and paclitaxel treatment was increased 
from three to six days (Figure 5.6b).  
 
 
Figure 5.6: The relationship between vimentin intermediate filament integrity and chordoma 
cell response to cytotoxic chemotherapy drugs. (a) The percent cell survival of siNEG- and 
siVIM-cells treated with 20 µM cisplatin or 5 µM paclitaxel for 3 days. Data are reported as 
the average ± SEM; (b) The percent cell survival of siNEG- and siVIM-cells treated with 20 
µM cisplatin or 5 µM paclitaxel for 6 days. Data are reported as the average ± SEM.   
 
5.3.6 Substrate Stiffness Modulation Does Not Affect Chordoma Cell Resistance to 
Chemotherapeutic Agents 
 To further investigate the relationship between mechanical cues and chordoma 
cell chemoresistance, we cultured chordoma cells on substrates of variable stiffness and 
analyzed cell viability following treatment with cisplatin. As previously described 
(Chapter 4.3.1), we found chordoma cell area was significantly increased (Figure 5.7a) 
and cell circularity was significantly decreased (Figure 5.7b) on stiff (glass, 13 kPa PA 
gels) compared to soft (BME gels, 1 kPa PA gels) substrates. Despite significant 
differences in cell morphology, the sensitivity of chordoma cells to cisplatin was not 





survivals of cells on soft substrates (BME, 1 kPA PA gels) were not statistically 
different than those of cells on stiff substrates (13 kPa PA gels, glass) (Figure 5.7c). 
 
 
Figure 5.7: The effect of substrate stiffness on chordoma cell morphology and response to 
cisplatin. (a) The average cell area of chordoma cells cultured on BME gels, 1 and 13 kPa PA 
gels, and glass substrates reported as the average ± SEM. *p<0.05; ****p<0.0001; (b) The 
average cell circularity of chordoma cells cultured on BME gels, 1 and 13 kPa PA gels, and 
glass substrates reported as the average ± SEM. ***p<0.001; ****p<0.0001; (c) The percent 
cell survival of chordoma cells cultured on different substrates treated with 20 µM cisplatin 




 Patients diagnosed with chordoma are typically given a poor prognosis, due to 
high recurrence rates and treatment difficulties [172], [173]. Because chordomas grow 





difficult and often impossible. Radiation therapy and chemotherapy have also proven 
ineffective treatments, as chordomas are resistant to both [1], [66], [174]. Currently no 
systemic drugs are approved by the FDA for treatment of chordoma. Presumably due 
to its rarity, few studies of chordoma have been performed at the molecular level. 
However, such studies are necessary to identify and improve our understanding of 
factors that contribute to chordoma formation and progression. Ultimately, this 
knowledge may assist in the development of effective treatments. 
 IFs, both vimentin and cytokeratins, have individually been found to play roles 
in cell migration, invasion, and chemoresistance and their co-expression is suggested 
to promote a malignant cell phenotype [17]. Additionally, EMT, characterized by 
increased vimentin expression, is associated with cancer metastasis and poor prognosis 
[15], [18], [19], [104]. However, the roles of vimentin and cytokeratin IFs in chordoma 
cell motility and chemoresistance have not been reported. Results of this study reveal 
that vimentin expression may contribute to chordoma progression. Specifically, 
decreased vimentin expression in chordoma cells inhibited cell migration, invasion, and 
decreased the expression of the chordoma biomarker, SHH. Our results also suggest 
that vimentin expression may play a role in chordoma chemoresistance.  
 The roles of vimentin and cytokeratin-8 IFs in chordoma cell migration in 2D 
were investigated using a modified wound healing assay. Similar to previous reports 
[184], [185] we observed chordoma cells to migrate at a slow rate and therefore 
examined cell migration over a four-day period. On bare and collagen-coated plastic, 
we found migration was significantly decreased in vimentin and cytokeratin-8 





cytokeratin knockdown in other types of cancer cells. Down-regulation of vimentin has 
been found to decrease cell migration in cells that express only vimentin IFs, such as 
fibroblasts, in addition to cells that co-express vimentin and cytokeratin IFs, such as 
colon cancer cells [10], [12]. Similarly, down-regulation of cytokeratins 8 or 18 
decreased cell migration, without modulating vimentin expression, in non-small lung 
cancer and oral squamous cell carcinoma [9], [84]. Collectively, these data strongly 
suggest that both vimentin and cytokeratin IFs play a role in chordoma cell migration. 
 We observed the migration of all cell types was inhibited on laminin-coated 
substrates compared to bare and collagen-coated substrates. Immunohistological 
examination has previously revealed expression of both laminins and type I collagen 
in chordomas [186]. Type I collagen has been found to be the predominant collagenous 
protein within chordomas [186], and cell proliferation has previously been shown to 
increase in chordoma cell lines cultured on type I collagen substrates [68]. The 
differences we observed in chordoma cell migration when cultured on different 
substrate proteins may be attributed to differences in the expression levels of collagen- 
and laminin-binding integrins. The density and distribution of laminin versus type I 
collagen across the cell culture surface may also be different, despite our use of similar 
protein concentrations. Both integrin and ligand density can affect cell migration, 
where intermediate expression levels and cell-substrate adhesions supports maximum 
migration [187].  
 Cell invasion assays were completed to determine the potential effects of 
vimentin and cytokeratin-8 knockdown on cell migration through a physical barrier of 





cells to pass through the basement membrane and ECM. Tumor cells that have acquired 
the ability to invade the surrounding tissues tend to progress to intravasation, which 
ultimately leads to cancer metastasis. For our studies, we utilized Corning Fluoroblok 
24-multiwell insert plates with PET membranes (3 µm pores). To serve as a barrier and 
occlude pores, membranes were coated with Corning Matrigel Matrix, a basement 
membrane preparation derived from EHS mouse sarcoma. Matrigel is composed of 
laminin, collagen IV, heparin sulfate proteoglycans, entactin/nidogen, and a variety of 
growth factors. As expected, we found significantly fewer chordoma cells invaded 
through the Matrigel matrix when vimentin expression was decreased. This result is 
consistent with previous reports of decreased cell invasion in vimentin-deficient cells 
[12] and the correlation between tumor metastasis and vimentin overexpression [15], 
[17]–[19]. Despite decreased cell migration in 2D, we did not observe any differences 
in cell invasion as a result of cytokeratin-8 knockdown. Cell migration and invasion 
were found to be uncoupled in other cell types. For example, pre-EMT rat prostate 
cancer cells were more migratory than their post-EMT counterpart, but the opposite 
trend was observed for cell invasion [188]. Post-EMT, but not pre-EMT, cells were 
vimentin positive. Consistent with our results, this suggests vimentin IFs, rather than 
cytokeratin IFs, play a more prominent role in chordoma cell invasion.   
 Invasive cancer cells have previously been characterized as being more 
deformable than non-invasive cells [189], likely aiding in their ability to penetrate 
through small spaces. Consequently, cell deformability is emerging as a biomarker for 
malignant cells [115], [190]. Our vimentin knockdown chordoma cells have proven to 





found both chordoma cell stiffness (Chapter 4.3.4) and invasion to be significantly 
decreased in cells with decreased vimentin expression. Therefore, in addition to cell 
deformability, we suggest vimentin expression should be taken into account when 
examining and characterizing cancer cells.   
 We found siRNA-mediated vimentin knockdown was maintained for two 
weeks. Following siRNA transfection, we consistently observed little to no cell 
proliferation within the first week of culture. We hypothesize that decreased cell 
proliferation is the primary reason for stable vimentin knockdown, as previous reports 
show that siRNA-mediated protein knockdown can last 3-4 weeks in non-dividing cells 
[191]. Examining the effect of vimentin knockdown on chordoma phenotypic gene 
expression, we found that siVIM-cells exhibited significant downregulation of SHH 
expression relative to control, siNEG-cells 14 days after transfection on type I collagen 
coated plastic. A positive correlation between SHH and vimentin expression has 
previously been demonstrated in other cell types. For instance, increased expression of 
SHH upregulated vimentin in pancreatic cancer cells [130]. Similarly, activation of the 
SHH signaling pathway has been found to promote EMT, where vimentin is a key 
mesenchymal marker [126], [127], [130]. Increased expression of SHH has been 
associated with tumor formation and progression in various cancers and is believed to 
play a role in the malignant transformation of notochordal remnants [124], [182].  
Interestingly, differences in SHH expression were not detected between siVIM- 
and siNEG-cells cultured on top of (2D) or embedded within (3D) type I collagen gels. 
Substrate rigidity and its effect on cell proliferation and SHH signaling may be 





coated plastic and collagen gels. Cancer cell proliferation, associated with SHH 
signaling [192], [193], often increases with increasing substrate stiffness [194].  It has 
also been shown that the expression of Gil2, a mediator of SHH signaling, was 
upregulated in breast cancer cells on rigid compared to compliant substrates [195]. In 
contrast to the stable knockdown of vimentin over a fourteen-day period, cytokeratin-
8 knockdown was transient in siKRT8-cells. Therefore, we were unable to determine 
the effect of long-term cytokeratin-8 knockdown on the expression of phenotypic 
genes.  
Finally, we investigated the involvement of IFs in chordoma cell resistance to 
the commonly used chemotherapeutic agents, cisplatin and paclitaxel. Cisplatin’s 
reported mechanism of action is through DNA binding and initiation of apoptosis. 
Paclitaxel inhibits cell division through specific binding to and stabilization of 
microtubules. Previous studies have demonstrated increased cisplatin and paclitaxel 
sensitivity in vimentin- and cytokeratin-deficient cancer cells; however, the 
mechanisms are not fully understood. Cytokeratin expression has been associated with 
apoptotic resistance in both normal and malignant epithelial cells [196], [197], 
presumably providing specific resistance to the apoptotic effect of TNFα via 
moderation of TNFα-mediated NF-κB activity [11], [196]. Vimentin IFs have been 
shown to interact with proteins, such as phosphorylated Erk (pErk) MAP kinases [198], 
involved in cell signaling pathways critical in cell proliferation and apoptosis. To gain 
a better understanding of the potential relationship between cytotoxic drug treatment 
and IF integrity, we visualized the cytoskeleton of chordoma cells treated with 





cell nucleus in cisplatin-treated cells. The cytoskeleton, including cytokeratin IFs, has 
previously been shown to collapse and aggregate around the nucleus in cells treated 
with cisplatin [199]. Collapse of the cytoskeletal network was only partially reversible 
when cells were allowed to recover in drug-free growth media, suggesting cisplatin 
may target other cellular components in addition to DNA [199]. We also observed an 
increase in vimentin fluorescence intensity in chordoma cells treated with cisplatin. 
Others have reported that cisplatin treatment increases vimentin expression and 
migration in residual cancer cells [200]. Therefore, supplementing chemotherapy with 
molecules targeting the EMT pathway may reduce tumor recurrence.  
To further explore potential interactions between IF integrity and 
chemoresistance, we examined the viability of day fourteen vimentin knockdown cells 
treated with cisplatin and paclitaxel. Cytokeratin-8 knockdown cells were not included 
in these analyses due to transient knockdown. We chose to increase the length of cell 
culture time between siRNA transfection and cisplatin/ paclitaxel treatment to promote 
potential cell phenotypic changes initiated by vimentin knockdown and give cells 
sufficient time to recover from the transfection process, which appeared to encourage 
chemoresistance. For instance, when cells were examined only six days after siRNA 
transfection, nearly 90% of transfected (siNEG) cells survived cisplatin treatment, 
compared to approximately 70% cell survival in non-transfected chordoma cells. When 
treated with cisplatin and paclitaxel, we consistently observed vimentin knockdown 
cells to have decreased cell survival compared to control cells; however, these 
differences were not statistically significant. In agreement, EMT suppression and 





lung cancer and gastric cancer cells to cisplatin [20], [22]. These results suggest that 
vimentin overexpression may contribute to chordoma chemoresistance and targeting 
vimentin or EMT pathways may increase chordoma cell sensitivity to cytotoxic agents.  
 We also examined the effects of substrate stiffness on the chordoma cell 
response to chemotherapy. To do this, we generated substrates of varying stiffness 
(BME gels, 1 and 13 kPa laminin-coated PA gels, and laminin-coated glass) and treated 
chordoma cells adhered to these substrates with cisplatin. Consistent with our previous 
observations (Chapter 4.3.1), we found untreated chordoma cells were significantly 
more spread, measured by increased cell area and decreased circularity, when cultured 
on stiffer substrates. Despite changes in cell morphology, we did not find that chordoma 
cells were more or less sensitive to cisplatin when substrate stiffness was altered. 
Similar to our findings, pancreatic cancer cells treated with gemcitabine, a cytotoxic 
drug that incorporates into DNA and RNA, exhibited changes in vimentin expression 
and their resistance was not affected by substrate rigidity [179]. However, other groups 
have observed that increasing or decreasing substrate stiffness can promote cell 
resistance to chemotherapy drugs. For instance, hepatocellular carcinoma cells were 
more resistant to cisplatin when cultured on stiffer (12 vs. 1 kPa) PA gels [201], and 
breast cancer cells were more resistant to cisplatin and paclitaxel when cultured on 
softer PDMS substrates [202].  Because the effects of substrate stiffness on 
chemoresistance are commonly attributed to EMT, the changes we observed in 
vimentin and cytokeratin-8 IFs following cisplatin treatment may explain the similar 
chemo-response of chordoma cells across all substrates. Future comparisons of IF 





stiff substrates may improve our understanding of this relationship. Examining 




 Results of this study demonstrate that chordoma cell migration and invasion 
depend on vimentin IFs. The role of vimentin IFs in cancer cell motility and resulting 
metastasis is commonly accepted, and this is the first study to confirm this role in 
chordoma cells. Chordoma cell migration was also dependent on cytokeratin-8 IFs. 
However, knockdown of cytokeratin-8 IFs did not prevent chordoma cell invasion. We 
also observed decreased SHH expression in chordoma cells lacking vimentin, further 
supporting the involvement of vimentin IFs in chordoma progression. A positive 
correlation between vimentin and SHH expression has been observed in other cancers 
and SHH expression is commonly associated with tumor formation and progression. 
Finally, our results suggest that overexpression of vimentin may encourage chordoma 
cell resistance to cytotoxic chemotherapy drugs. Overall, chordoma cells expressing 
vimentin were associated with a more malignant and metastatic cell phenotype. 
Currently, chordomas are often associated with a poor prognosis because they are 
difficult to treat and have a propensity for recurrence. Elucidating biological factors 
that encourage chordoma progression and chemoresistance is essential for the 






Chapter 6: Conclusions and Future Work 
 
The overall goal of this work was to determine the functional roles of vimentin 
and cytokeratin IFs in the mechanobiology and progression of chordoma. Normal cell 
functioning is dependent on the cytoskeleton. Most cell processes, such as cell division, 
mechanotransduction, and migration, are attributed to microtubules and actin 
microfilaments, while the roles of IFs are often overlooked. In fact, IFs were initially 
believed to be static networks that only served a structural role. More recent evidence 
supports the involvement of IFs in cell mechanical properties and processes; however, 
the functional roles of IFs remain unclear.  
 Co-expression of vimentin and cytokeratin IFs has been reported in a variety of 
different types of cancer cells, indicating a hybrid cell phenotype that has not fully 
completed EMT or vice versa. The ability of cells to maintain a hybrid phenotype, 
expressing features of both mesenchymal (vimentin) and epithelial (cytokeratin) origin, 
may promote a more aggressive malignancy [23]. However, the mechanisms 
responsible for the reported increase in malignant behaviors of cells in partial EMT is 
unknown and may be elucidated through the examination of vimentin and cytokeratin 
IFs. To investigate this, we decreased vimentin and cytokeratin-8 expression in 
chordoma cells using RNAi and examined the resulting effects on cell phenotype, 






Figure 6.1: Schematic of the objectives of the three aims completed in this work. Using RNAi, 
the effects of cytokeratin-8 and vimentin knockdown on the phenotype (Aim 1), 
mechanobiology (Aim 2), and characteristic malignant behaviors (Aim 3) of chordoma cells 




6.1 Cytosolic Vacuoles of Chordoma Cells Are Dependent on Cytokeratin-8 
Intermediate Filaments 
The first objective of this work was to determine the phenotypic changes of 
chordoma cells following vimentin and cytokeratin-8 knockdown. Optimal knockdown 
was achieved six days after transfection with siRNA, and was verified at the mRNA 
level, using qRT-PCR, and the protein level, using western blotting and 
immunofluorescence. Vimentin and cytokeratin-8 knockdown cells were specifically 
examined for their tendency to organize in dense cell clusters, the presence of cytosolic 
vacuoles, and their expression of genes characteristically expressed in notochordal and 





which is marked by decreased cytokeratin-8 expression and increased vimentin 
expression [44], [48]. Therefore, we hypothesized that decreasing cytokeratin-8 
expression in chordoma cells, which originate from notochordal remnants [52], would 
stimulate other characteristic developmental changes such as a loss of cytosolic 
vacuoles and decreased cell clustering. Surprisingly, knockdown of cytokeratin-8 did 
not affect chordoma cell clustering or the expression of the notochordal markers T 
brachyury, SHH, or N-cadherin. These results were also consistent for vimentin 
knockdown cells. However, cytokeratin-8 knockdown did reduce the number of 
cytosolic vacuoles per cell compared to control and vimentin knockdown cells. 
In support, we also observed cytokeratin-8 IFs organized immediately around 
chordoma cell vacuoles. This peri-vacuolar relationship was not observed for other 
cytoskeletal elements including vimentin. Further, we found disruption of the IF 
network with acrylamide significantly decreased the number of cytosolic vacuoles in 
chordoma cells. Although vacuole loss was also observed as a result of F-actin 
disruption with cytochalasin-D and microtubule disruption with nocodazole, vacuole 
loss was the greatest in cells treated with acrylamide. Together, these results suggest 
that IFs, specifically those containing cytokeratin-8 proteins, are critical for the 
vacuolation of chordoma cells.  
Further work needs to be completed to elucidate the mechanisms in which 
cytokeratin-8 IFs contribute to chordoma cell vacuolation. Due to the gradual process 
of IF protein knockdown, we were unable to determine the change in the number of 
vacuoles for a particular cell as a direct result of knockdown. Consequently, it is not 





cytokeratin-8 expression. Additional studies of the involvement of cytokeratin-8 IFs in 
notochord morphogenesis would provide clarity of how cytokeratin-8 may participate 
in vacuologenesis. While chordomas are commonly identified and distinguished from 
other tumors by their vacuoles, the significance of chordoma cells maintaining 
cytosolic vacuoles is unknown. The identification of cytokeratin-8 IFs as a critical 
component for the existence of cytosolic vacuoles could assist future studies aimed to 
characterize the contents and functions of chordoma cell vacuoles.  
 
6.2 Chordoma Cell Mechanosensing, Traction Forces, and Stiffness Are Dependent on 
Vimentin Intermediate Filaments 
 Our second objective was to determine the roles of vimentin and cytokeratin-8 
IFs in chordoma cell mechanobiology, as mechanical cues are essential determinants 
of cell functions and are often used as cancer biomarkers. Using vimentin and 
cytokeratin-8 knockdown cells characterized in our first study, we examined cell 
stiffness, traction forces, and sensitivity to substrate stiffness. Brillouin microscopy 
was used to directly measure cell longitudinal modulus and subsequently determine 
cell stiffness. We found the longitudinal modulus of vimentin knockdown cells was 
significantly decreased compared to control and cytokeratin-8 knockdown cells, 
indicating vimentin IFs contribute to chordoma cell stiffness. While cell stiffness has 
predominately been attributed to F-actin, previous reports have also found vimentin IFs 
contribute to cell stiffness [4], [8], [85], [170]. Interestingly, metastatic cells have been 
found to be more deformable than their non-metastatic counterparts, and deformability 





was used as a cancer biomarker in our study, vimentin knockdown cells would be 
categorized as more metastatic. This is contradicting to the generally accepted 
correlation between vimentin expression and metastasis.  
Using traction force microscopy, we determined vimentin knockdown also 
affected chordoma cell traction forces. Specifically, we found chordoma cells with 
decreased vimentin expression exerted significantly greater traction forces than control 
and cytokeratin-8 knockdown cells. Because these differences were not maintained 
when cells were treated with blebbistatin, a myosin II inhibitor, we postulate greater 
traction forces in vimentin knockdown cells were a result of F-actin over compensation. 
This relationship between vimentin knockdown, actin stress fiber assembly, and 
increased traction forces has previously been observed in osteosarcoma cells [6].   
Finally, we found vimentin knockdown disrupted chordoma cell sensitivity to 
substrate stiffness. To examine cell mechanosensitivity, cell area and circularity were 
measured of knockdown cells cultured on PA gels of variable stiffness. Typically, cell 
spread area increases with increasing substrate stiffness [165]. This behavior was 
confirmed in control cells and was not affected by cytokeratin-8 knockdown. In 
contrast, vimentin knockdown cells cultured on soft (0.42kPa), Col-PA gels exhibited 
significant cell spreading. This result contradicts previous reports of vimentin 
knockdown reducing cell spreading [166], [167]. It is possible that residual vimentin, 
and its strong association with cell protrusions and focal adhesions, is contributing to 
the increased spreading of vimentin knockdown cells. Overall, our findings suggest 
that vimentin IFs contribute to chordoma cell mechanobiology to a greater extent than 





of their surrounding ECM is critical for proper cell function. Therefore, we predicted 
chordoma cell behaviors such as cell migration and invasion will be dependent on 
vimentin expression.  
 Additional studies could be completed to further understand the implicated role 
of vimentin IFs in chordoma cell stiffness, traction forces, and mechanosensitivity. In 
this work we measured the longitudinal moduli and traction forces of cells cultured on 
5 kPa PA gels. Because we determined vimentin knockdown dysregulated chordoma 
cell sensitivity to substrate stiffness, it would be interesting to examine how decreased 
vimentin expression affects cell stiffness and traction forces across a range of substrate 
stiffness. The ability of cells to sense and respond to the mechanical properties of their 
surrounding ECM, typically through mirrored increases in cell stiffness and traction 
forces, may be dependent on vimentin expression. The localization of residual vimentin 
in vimentin knockdown cells to the cell periphery, particularly within cell protrusions, 
may be a factor contributing to the results we observed in this study. To differentiate 
the effects of decreased vimentin expression from those of residual vimentin 
localization, complete ablation of vimentin is required. 
 
6.3 Vimentin Expression is Associated with Metastatic Behaviors in Chordoma Cells 
The third and final objective of this work was to improve our understanding of 
how vimentin and cytokeratin-8 IFs are involved in cell behaviors that promote the 
progression of chordoma. Based on the observed effects of vimentin knockdown on 
chordoma cell stiffness and mechanosensitivity, we predicted vimentin knockdown 





generated vimentin and cytokeratin-8 knockdown cells via RNAi. Using these 
knockdown cells, we analyzed cell migration in 2D culture, cell invasion through an 
ECM-like barrier, gene expression of chordoma biomarkers, and cell sensitivity to 
traditional cytotoxic chemotherapeutics. Similar to previous reports [9], [10], [12], 
[84], we observed decreased cell migration as a result of both vimentin and cytokeratin-
8 knockdown. For vimentin knockdown cells, this effect on cell motility was translated 
to cell invasion, which was also significantly decreased. Interestingly, chordoma cell 
invasion was not affected by decreased cytokeratin-8 expression. These results are 
consistent with previous reports that reveal migration and invasion are uncoupled 
[188], and vimentin expression is positively correlated with cancer metastasis [15], 
[17]–[19]. 
Although short-term (processed for analysis six days after transfection with 
siRNA) vimentin and cytokeratin-8 knockdown cells did not exhibit changes in gene 
expression of chordoma biomarkers, we found long-term (processed for analysis 
fourteen days after transfection with siRNA) vimentin knockdown resulted in 
decreased SHH expression. In contrast to vimentin knockdown, cytokeratin-8 
knockdown was transient and therefore the effects of long-term cytokeratin-8 
knockdown on biomarker expression could not be determined.  Expression of SHH has 
been associated with tumor formation and progression in other cancers, and the 
reactivation of SHH in notochordal remnants is believed to stimulate a malignant 
transformation [124], [130], [182]. Therefore, our results suggest that vimentin 





Our final analysis was focused on determining the potential involvement of IFs 
in the resistance of chordoma cells to cytotoxic chemotherapy drugs. Expression of 
both vimentin and cytokeratin-8, in addition to cell mechanobiology, has previously 
been associated with cancer cell chemoresistance [11], [20]–[22], [84], [179]. Analysis 
of vimentin knockdown cells suggests that decreased vimentin expression could 
potentially increase the efficiency of cisplatin and paclitaxel in treating chordoma. 
Through immunofluorescence, we observed the fluorescence intensity of vimentin IFs 
to be greater in chordoma cells treated with cisplatin compared to untreated chordoma 
cells. This suggests that chemotherapy may encourage vimentin expression and cancer 
metastasis in residual cells [200]. In combination with chemotherapy, vimentin could 
be utilized as a molecular target to increase cell sensitivity and prevent tumor 
recurrence.  
 Further studies need to be completed to form a more comprehensive 
understanding of the relationship between IFs, substrate stiffness, and migration. To 
complement our analysis of 2D cell migration on plastic substrates, the migration of 
knockdown chordoma cells could be analyzed on softer substrates such as type I 
collagen gels. Gels with a stiffness gradient could also be designed to investigate the 
roles of vimentin and cytokeratin-8 IFs in chordoma cell durotaxis. Future studies 
should also explore the role of vimentin and cytokeratin-8 IFs in chordoma cell 
proliferation, which could further improve our understanding of chordoma progression 
and chemoresistance, as rapidly dividing cells tend to be more responsive to cytotoxic 
drugs. While initial findings suggest that decreasing vimentin expression increases the 





to be completed to confirm these results. In addition to examining chordoma cell 
chemoresistance in monolayer culture, a more physiologically relevant culture system 
should be designed and utilized to better understand how these effects may translate in 
vivo. Compared to monolayer cell culture, cells in 3D culture tend to proliferate slower, 
and as a result will probably respond differently to cytotoxic drug treatment. Therefore, 
it is necessary to also examine the effects of administering chemotherapeutics to 
vimentin knockdown chordoma cells embedded within a 3D scaffold composed of 
proteins characteristic of chordoma, such as type I collagen. 
 
6.4 Concluding Remarks 
 Our results suggest that vimentin and cytokeratin-8 IFs have specific functional 
roles in chordoma cells. While cytokeratin-8 expression was essential for the presence 
of cytosolic vacuoles, vimentin expression was essential for cell mechanosensing of 
substrate stiffness and contributed to cell stiffness. Presumably due to its greater 
contribution to chordoma cell mechanobiology, vimentin expression was also essential 
for chordoma cell invasion, the expression of the chordoma biomarker sonic hedgehog, 
and was associated with increased cell resistance to cisplatin and paclitaxel. For the 
first time, these results elucidate roles of vimentin and cytokeratin-8 IFs in chordoma 
cell mechanobiology and suggest a correlation between vimentin expression and 
malignant behaviors in chordoma cells. 
Overall, this work shows IFs are essential, dynamic components of the 
cytoskeleton and – similar to microtubules and actin microfilaments – are critical for 
normal cell functioning. More specifically, our findings improve our knowledge of IFs 





progression of cancer is influenced by changes in the biomechanical properties of cells 
and their surrounding environment. Identifying cellular components that play key roles 
in these processes and are uniquely or overexpressed in cancer is necessary for the 







Appendix A: Phenotype of Rat Nucleus Pulposus Cells: 
Effects of the Extracellular Environment and a Comparison 
to Chordoma Cells 
 
 Prior to focusing on chordoma cells, I primarily worked with NP cells isolated 
from rat caudal IVDs. As the NP and chordoma are both derived from the embryonic 
notochord, I chose to include this work. Included here is a study examining the effects 
of the extracellular environment on the morphology of NP cells, in addition to a 
phenotypic comparison of rat NP and human chordoma cells.  
 
A.1 Introduction 
 The NP tissue of the IVD is generally considered to be populated by two major 
cell types: NCs (immature NP cells) and chondrocyte-like cells. As humans age, NCs, 
characterized by their large size and abundant cytosolic vacuoles, tend to be replaced 
and/or supplanted by chondrocyte-like cells. The cellular transition from NCs to mature 
NP cells coincides with age-associated changes in the NP ECM such as decreases in 
water and proteoglycan content [44], [119], [100], [120] and increased tissue stiffness 
[158], ultimately impairing the tissue’s ability to behave hydrostatically and withstand 
compression [203]. As a result, the IVD becomes more susceptible to disc degeneration 
and resulting low back pain [121], [122]. 
 Because cells of the NP are responsible for the synthesis of a functional ECM, 
the cellular transition observed with aging is believed to be involved in the progression 
of disc degeneration [49], [50]. Changes in cell morphology have been shown to play 
a role in the NP cellular transition. For instance, previous studies of rat NP cells in vitro 





expression [142]. Therefore, our objective was to investigate the role of extracellular 
cues in governing morphological changes in NP cells. In this study, we examined the 
morphological consequences of culturing NP cells on collagen substrates of different 
stiffness and configuration. In order to implement a well-controlled, systematic 
approach, we utilized type I collagen thin films (CTFs), a 2-D platform for cell culture 
developed by the National Institute of Standards and Technology. We were able to 
manipulate the stiffness of CTFs through dehydration, where dehydrated TFs (3x10-2 
N/m ± 2x10-2 N/m) are stiffer than hydrated TFs (3x10-3 N/m ± 2x10-3 N/m) [204]. 
We found that NP cells cultured on hydrated CTFs had significantly smaller cell areas, 
corresponding to more circular morphologies, compared to NP cells on dehydrated 
CTFs, absorbed collagen molecules, and TCTP. That dehydrated CTFs, adsorbed 
collagen, and TCTP yielded similar results suggests that collagen stiffness, rather than 
collagen configuration, has a dominant effect on NP cell morphology.  
 Further, we compared the phenotype of rat NP cells to that of human chordoma 
cells derived from the MUG-Chor1 cell line that was utilized in this dissertation. 
Characteristic of NCs, both cell types contained cytosolic vacuoles and co-expressed 
cytokeratin and vimentin IFs. However, the vimentin IF network appeared to be more 
prominent in chordoma cells than in rat NP cells.  
 
A.2 Materials and Methods 
A.2.1 Nucleus Pulposus Tissue Harvest and Cell Isolation 
 NP tissue was harvested from caudal discs of adult Sprague-Dawley rats after 





type II collagenase overnight. All procedures were approved by the Institutional 
Animal Care & Use Committee. 
 
A.2.2 Collagen Thin Film Preparation 
 Type I collagen solutions consisting of 87.5% 1x DPBS (Sigma-Aldrich), 10% 
3 mg/ml bovine type I collagen (Advanced Biomatrix), 1.25% 0.1N NaOH, and 1.25% 
10x DPBS (Sigma-Aldrich) were prepared and incubated in six-well non-tissue culture-
treated polystyrene plates (1-2 ml/well) overnight. Surfaces were then rinsed with PBS, 
followed by deionized water, and sprayed briefly with inert nitrogen gas to form CTFs. 
PBS was added immediately to hydrated CTFs, whereas dehydrated TFs were dried for 
24 hours before the addition of PBS. 
 
A.2.3 Cell Culture 
 Immediately following isolation, NP cells were seeded at a density of 3,000 
cells/cm2 on either hydrated type I CTFs, dehydrated type I CTFs, absorbed type I 
collagen (50 μg/ml) molecules, or TCTP. NP cells were cultured in α-MEM 
supplemented with 2% FBS (Gibco/Thermo Fisher) and 1% Penicillin-Streptomycin 
(Gibco/Thermo Fisher). MUG-Chor1 chordoma cells (ATCC Cat# CRL-3219, 
RRID:CVCL_9277) were cultured in Iscove's Modified Dulbecco's Medium: Roswell 
Park Memorial Institute 1640 Medium (4:1) (Gibco/Thermo Fisher Scientific) 
supplemented with 10% FBS (Gibco/Thermo Fisher) and 1% Penicillin-Streptomycin 
(Gibco/Thermo Fisher). Complete media exchange was completed every 2-3 days and 






A.2.4 Morphological Analysis 
 NP cells were fixed on either day 3 or day 7 of culture in 4% PFA, 
permeabilized with 0.1% Triton-X in PBS, and blocked for non-specific binding using 
1.5% normal goat serum (NGS) in PBS. Cells were then incubated with 2.5% Alexa 
Fluor® 594 Phalloidin (Molecular Probes, Eugene, OR) to stain the actin cytoskeleton 
and DAPI (Molecular Probes) used as a nuclear counterstain. Cells were imaged at 
x100 magnification with a Nipkow (spinning) disk-equipped Olympus IX81 
microscope, and Image J was used to measure the area and perimeter of each cell with 
a single nucleus. Shape factor, a measure of cell circularity, was calculated for each 




 Immunofluorescence was used to visualize IFs in NP and chordoma cells. As 
previously described, cells were fixed with 4% PFA, permeabilized using 0.1% Triton 
X-100, and blocked for non-specific binding using 1.5% NGS. For vimentin, rat NP 
and human chordoma cells were labelled with rabbit IgG anti-vimentin polyclonal 
(Abcam) and rabbit IgG anti-vimentin [SP20] (Thermo Fisher Scientific) antibodies, 
respectively. A biotinylated (anti-rabbit IgG) secondary antibody (Vector Laboratories) 
was used in combination with FITC-labelled streptavidin (Vector Laboratories) to 
visualize vimentin. For cytokeratins, rat NP and human chordoma cells were labelled 





594-conjugated (anti-mouse IgG) secondary antibody (Thermo Fisher Scientific) was 
used to visualize cytokeratins 8, 18, and 19. DAPI (Invitrogen/Thermo Fisher 
Scientific) was used as a nuclear counterstain. Confocal fluorescence images were 
captured at x600 magnification using a Nipkow (spinning) disk-equipped Olympus 
IX81 microscope and Z-stacks (1 μm slices) were projected into a single image. 
 
A.2.6 Statistical Analysis 
 Statistical significance between time points was determined using a two-tailed 
t-test, while ANOVA with Tukey’s post-hoc analysis was used to compare substrates 
within each time point. Due to unequal variances, cell area among substrates within 
time points were further analyzed for significance using Kruskal-Wallis and Mann-
Whitney tests. For all analyses, critical significance levels were set to α = 0.05. Average 
cell areas are reported as mean ± SEM. 
 
A.3 Results 
A.3.1 Substrate Stiffness Modulates Nucleus Pulposus Cell Morphology 
 NP cells seeded on hydrated CTFs had significantly smaller cell areas than NP 
cells seeded on dehydrated CTFs, adsorbed collagen, and TCTP (Figure A.1a, b). This 
result was observed on both days three and seven of cell culture. On day seven of 
culture, NP cells cultured on stiffer substrates (TCTP, absorbed collagen, dehydrated 
CTFs) became more spread with visible actin stress fibers (Figure A.1a). In contrast, 
NP cells on hydrated CTFs remained more rounded (Figure A.1a).  Analyzing cell 





day three and between hydrated CTFs and all other surface types (TCTP, adsorbed 
collagen, and dehydrated CTFs) for day seven (Figure A.1c). Statistically significant 
differences were also found comparing day three and day seven data, where cells on 
day seven had larger cell areas and were more spread for all surface types. 
 
 
Figure A.1: The effect of type I collagen substrate configuration and stiffness on NP cell 
morphology. (a) Representative fluorescence images of NP cells cultured for seven days on 
TCTP, absorbed collagen, dehydrated CTFs, and hydrated CTFs. Stained for F-actin (red). 
Scale bars: 50 µm; NP cell (b) area and (c) shape factor on days 3 and 7 of culture on TCTP, 








Figure A.2: Frequency distributions of day three and day seven NP cell area and shape factor 
data. Non-linear regression analysis was used to fit a Gaussian (4 parameter) curve to the data.  
 
A.3.2 Rat Nucleus Pulposus and Human Chordoma Cells Contain Characteristic 
Features of Notochordal Cells 
 To verify and expand on previous studies characterizing the human chordoma 
cell line that we utilized for our studies, we compared the morphology and IFs of MUG-
Chor1 chordoma cells to rat NP cells. Rats are one of the vertebrates that have been 
shown to maintain large, vacuolated NCs in their NP throughout life. Similar to rat NP 
cells, we observed human MUG-Chor1 chordoma cells contained cytosolic vacuoles 





a heterogeneous cell population, with many fibroblast-like cells in addition to larger, 
vacuolated cells (Figure A.3c). With prolonged culture in monolayer, the number of 
vacuolated cells appeared to increase (Figure A.3c). Visualizing vimentin and 
cytokeratin (8, 18, 19) IFs via immunofluorescence, we observed positive cytokeratin 
IF staining in both rat NP and human chordoma cells (Figure A.3b). However, vimentin 
fluorescence was noticeably weaker in rat NP cells compared to chordoma cells (Figure 
A.3b). While a continuous vimentin IF network was observed throughout the cell body 








Figure A.3: Comparison of NP and chordoma cell phenotypes in monolayer culture. (a) Bright 
field images of a rat NP cell and a human chordoma cell showing cytosolic vacuoles. Scale 
bars: 25 µm; (b) Representative fluorescence images of rat NP cells and human chordoma cells. 
Cytokeratins 8, 18, 19 (red) and vimentin (green). Scale bars: 10 µm; (c) Representative bright 
field images of human chordoma cells in monolayer culture at low and high and cell densities. 
Red arrows indicate individual, vacuolated cells in low cell density culture. Scale bars: 50 µm. 
 
A.4 Discussion 
 This study examines the role of type I collagen stiffness and configuration on 
NP cellular behavior. We specifically examined NP cell morphology (area and shape) 
to distinguish effects of various culturing conditions. Smaller cell areas and more 
rounded morphologies observed for NP cells seeded on hydrated type I CTFs are 
similar to previous studies of NP cells cultured in 3D alginate beads [142] and BME 
[144]. Comparing hydrated CTFs with dehydrated CTFs further supports the 
hypothesis that decreased substrate stiffness induces a more rounded morphology, as 
hydrated TFs have a stiffness of 3x10-3 N/m ± 2x10-3 N/m and dehydrated TFs have a 
stiffness of 3x10-2 N/m ± 2x10-2 N/m [204]. Studies by Rastogi et al. additionally found 
that notochordal gene expression was maintained in rat NP cells that exhibited a more 
rounded, less stretched morphology [142]. Collectively, this suggests that softer 
substrates should be used to maintain the NC phenotype in vitro. 
 The loss of NCs within the NP coincides with changes in the composition, such 
as decreased proteoglycan and water content [44], [119], [100], [120], and mechanical 
properties of the ECM [158]. Ultimately, these age-associated changes impair NP 
function and the IVD becomes more susceptible to degeneration [121], [122], [203]. 





NCs are actively being researched for their tissue regeneration potential. Studies have 
found NC secretions were capable of stimulating the synthesis of proteoglycans, a 
critical component of the NP, in mature NP cells  [205]–[207]. Additionally, NC 
conditioned media was found to drive human mesenchymal stem cell (hMSC) 
differentiation toward a young, NP-like phenotype [208]. Understanding factors 
involved in maintaining the NC phenotype is essential for the development of NC-
based therapies targeting disc degeneration. 
 We additionally compared the phenotype of rat NP cells to human chordoma 
cells. Similar to the NP, malignant chordomas are believed to originate from remnants 
of the embryonic notochord [33], [55]. However, the mechanisms responsible for the 
malignant transformation of NCs are not fully understood. Characteristic of NCs, we 
found both rat NP and human chordoma cells contained cytosolic vacuoles and co-
expressed vimentin and cytokeratin IFs. Interestingly, we observed via 
immunofluorescence a continuous vimentin IF network in chordoma cells, but not in 
NP cells. In NP cells, vimentin IFs were only observed in the cell periphery. This is 
supported by previous studies of cancer cells, where malignant and metastatic cells had 
increased vimentin expression compared to healthy cells [18], [19]. While our initial 
findings suggest that vimentin expression is increased in chordoma cells relative to NP 
cells, additional studies need to be completed to quantify vimentin gene and protein 
expression. Further comparison studies utilizing human, rather than rat, NP cells should 
also be completed. Elucidating molecular differences between healthy NC cells 
residing in the mature NP and malignant chordoma cells is critical for understanding 





Appendix B: Morphological Analysis of Chordoma Cells 
Measured with Brillouin Confocal Microscopy and Traction 
Force Microscopy 
 
 The morphology of the chordoma cells included in our studies examining cell 
stiffness (Chapter 4.3.4) and traction forces (Chapter 4.3.2) was analyzed by measuring 
cell spread area and circularity. This was accomplished by manually tracing individual 
cells in bright field images using ImageJ. We determined that the average cell area and 
circularity were not statistically different comparing siNEG-, siVIM-, and siKRT8-
cells measured with Brillouin confocal microscopy (Figure B.1) or traction force 
microscopy (Figure B.2). This suggests that the increased cell spreading we observed 
in siVIM-cells on 5 kPa PA gels (Chapter 4.3.1) was not a contributing factor to the 
decreased cell stiffness (Chapter 4.3.4) and increased cell traction forces (Chapter 
4.3.2) of siVIM-cells compared to siNEG- and siKRT8-cells.  
 
 
Figure B.1: Morphological analysis of knockdown chordoma cells measured with Brillouin 








Figure B.2: Morphological analysis of knockdown chordoma cells examined with traction 
force microscopy. Chordoma cell (a) area and (b) circularity reported as the average ± SEM. 
 
 We further examined the correlation of cell spreading with cell stiffness and 
traction forces. We observed a positive correlation between cell circularity and cell 
stiffness (Figure B.3b) and a negative correlation between cell area and cell stiffness 
(Figure B.3a) for all cell types (siNEG, siVIM, and siKRT8). On the other hand, we 
did not observe any correlation between cell spreading with average (Figure B.4) or 






Figure B.3: Relationship between chordoma cell morphology and longitudinal modulus. 








Figure B.4: Relationship between chordoma cell morphology and average traction forces. 







Figure B.5: Relationship between chordoma cell morphology and maximum traction forces. 
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